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Abstract
Hemorrhagic stroke is a dangerous form of stroke resulting from the rupturing of weakened blood
vessels, releasing blood that increases intracranial pressure and causes the death of surrounding tissue.
Treatment options are improving but remain limited, as evidenced by this condition being characterized
by high rates of mortality as well as long-term morbidity. Unregulated inflammatory responses that occur
following injury may be partially to blame for these poor outcomes. In response to any injury, the immune
system releases cytokines to recruit immune cell activation and promote inflammation. But after
hemorrhagic stroke, whether aneurysmal subarachnoid hemorrhage (aSAH) or intracerebral hemorrhage
(ICH), the rapid increase in inflammation and an imbalance of inflammatory cytokines can lead to the
development of secondary ischemic injury. Several animal models have been developed to investigate
these forms of stroke, and despite their shortcomings, these models have been crudely applied for the
study of neuroinflammation post-stroke. There is an imperative need to establish a clear and robust
animal model that accurately represents the condition taking place in human patients. This dissertation
work began with a systematic review of the literature to more clearly understand the work that has been
done in this area. Next, the endovascular puncture model of aSAH was utilized in rats. Tissue samples
were collected and compared to human blood and cerebrospinal fluid samples to assess for cytokine
changes. Lastly, collagenase mouse models for ICH were utilized to understand the changes that take
place in the TXNIP-NLRP3 inflammasome following stroke and the therapeutic effects of verapamil on
inflammatory, functional, and behavioral outcomes. This dissertation work adds to the body of literature
on the relationship between inflammation, cytokine release, and outcomes, which will ultimately allow for
the development of improved treatment protocols.
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ABSTRACT
Hemorrhagic stroke is a dangerous form of stroke resulting from the rupturing of
weakened blood vessels, releasing blood that increases intracranial pressure and causes
the death of surrounding tissue. Treatment options are improving but remain limited, as
evidenced by this condition being characterized by high rates of mortality as well as longterm morbidity. Unregulated inflammatory responses that occur following injury may be
partially to blame for these poor outcomes. In response to any injury, the immune system
releases cytokines to recruit immune cell activation and promote inflammation. But after
hemorrhagic stroke, whether aneurysmal subarachnoid hemorrhage (aSAH) or
intracerebral hemorrhage (ICH), the rapid increase in inflammation and an imbalance of
inflammatory cytokines can lead to the development of secondary ischemic injury.
Several animal models have been developed to investigate these forms of stroke, and
despite their shortcomings, these models have been crudely applied for the study of
neuroinflammation post-stroke. There is an imperative need to establish a clear and
robust animal model that accurately represents the condition taking place in human
patients.
This dissertation work began with a systematic review of the literature to more
clearly understand the work that has been done in this area. Next, the endovascular
puncture model of aSAH was utilized in rats. Tissue samples were collected and
compared to human blood and cerebrospinal fluid samples to assess for cytokine changes.
Lastly, collagenase mouse models for ICH were utilized to understand the changes that
take place in the TXNIP-NLRP3 inflammasome following stroke and the therapeutic
effects of verapamil on inflammatory, functional, and behavioral outcomes.
This dissertation work adds to the body of literature on the relationship between
inflammation, cytokine release, and outcomes, which will ultimately allow for the
development of improved treatment protocols.
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CHAPTER 1.

INTRODUCTION

Background
Hemorrhagic Stroke
Hemorrhagic stroke is a form of stroke that results from a blood vessel breaking
and releasing blood into the brain. This can happen due to the spontaneous bursting of the
arterial wall, head trauma, arteriovenous malformations, or a bleeding aneurysm. The
likelihood of having a hemorrhagic event is influenced by many factors such as age, sex,
diet, race, alcohol use, drug use, and hypertension (An et al., 2017; Grysiewicz et al.,
2008). Death of brain tissue in the affected area occurs as a result of increased
intracranial pressure and a cascading inflammatory response. Due to the complex
vasculature of the brain, these strokes can occur anywhere in the brain and affect many
inflammatory response systems. General prognosis is largely dependent upon the location
and size of the bleed, although each case is unique. The two main subtypes of
hemorrhagic strokes are aneurysmal subarachnoid hemorrhage (aSAH) and intracerebral
hemorrhage (ICH).
aSAH is caused when a ruptured cerebral aneurysm bleeds into the subarachnoid
space of the brain. The incidence of new cases of aSAH in the United States is about
30,000/y or 10/100,000 persons, which accounts for ~5% of all strokes (D’Souza, 2015).
Despite being a less-common form of stroke, aSAH accounts for about 40% of total
stroke deaths, with aSAH survivors often experiencing severe long-term disability and
reduced quality of life (Lichtman et al., 2011). While improvements in the treatment
methods used are reducing mortality rates, there remains a high burden of morbidity in
this group.
Similarly, although ICH accounts for only 10-15% of all strokes, mortality rates
after ICH can reach >50% (Rymer, 2011). Approximately 74% of those who do survive
experience some degree of physical impairment; affective and cognitive changes may
also occur (van Asch et al., 2010). Like aSAH, ICH occurs when vessels inside the brain
rupture. However, in ICH, the blood released forms a hematoma in the surrounding
tissue. As cerebral blood flow is altered, additional secondary events can occur, including
edema, increased intracranial pressure, and herniation of brain tissue. Further brain
damage results from activation of immune cells, such as macroglia, which drives
cytotoxic and oxidative responses with neurotoxic effects. Ultimately, these processes
culminate in cell death (Shao et al. 2019).
Common to both subtypes are the cascading effects of unmitigated inflammation
that can create additional sequelae that can lead to poor outcomes. Thus, whether
considered in the context of aSAH or ICH, an improved understanding of the
inflammatory response following hemorrhagic stroke will inform treatment options to
minimize mortality and morbidity for these clinical populations.
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Current Treatment Methods for Hemorrhagic Stroke
Over the past years, improved treatment options to stop or slow cerebral bleeding
have greatly decreased mortality of hemorrhagic stroke patients in the hyperacute period
(Cesarini et al., 1999). Upon presentation for emergency care, a diagnosis of aSAH or
ICH is made by computerized tomography (CT) scan, Magnetic resonance imaging
(MRI), or cerebral angiography (Josephson et al., 2014). Treatment should be initiated
rapidly; goals must be established that focus on interventions to stop or reduce bleeding
and maintain acceptable intracranial pressures. Induced hypertension is commonly used
to prevent cerebral ischemia (rather than the outdated triple H regimen). In the context of
aSAH, the repair of vascular damage is also a goal, with endovascular coils (some
biologically active), stents, and neurosurgical clips serving as options. Even in the bestcase scenario, all of these treatments are initiated some time after the hemorrhage has
occurred. This means that blood flow has already reduced to cerebral tissue and damage
has already begun. Gains in recovery rates could be found in the development of an
effective treatment that specifically manages the inflammatory response and could be
rapidly initiated after stroke.
The Role of Cytokines and the Neuroinflammatory Response
In the context of hemorrhagic stroke, breach of the blood-brain barrier (BBB)
disrupts normal inflammatory system homeostasis, setting up an environment ripe for the
development of further damage (Butler et al., 2020). Vessel rupture alone causes an
immediate, local inflammatory response. In this circumscribed area, the immune system
works to recruit fast-acting immune cells (such as neutrophils and platelets) to respond to
the bleeding. These immune cells release cytokines at the site of the rupture; their release
recruits additional immune cells to the damaged area. This signaling in turn increases
inflammation throughout the body, triggering a systemic response that can have many
downstream effects on systems around the body.
Most critical to this homeostasis is the proper regulation of T cells controlled by
external signals, such as those generated by cytokines (Smigiel et al., 2014). Cytokines
can be produced by leukocytes upon appropriate stimulation and induction of
inflammation (Zhang et al., 2007). Eight different cytokines, broadly recognized for their
role in inflammation, have also been described in the literature as playing an important
role in hemorrhagic stroke (Interleukin-1α [IL-1α], Interleukin-1β [IL-1β], Interleukin-4
[IL-4], Interleukin-6 [IL-6], Interleukin-8 [IL-8], Interleukin-10 [IL-10], Interleukin-12
[IL-12], Interleukin-13 [IL-13], and Tumor necrosis factor-alpha [TNF-α]). Some of
these cytokines act as pro-inflammatory signals, while others act as anti-inflammatory
signals (Zhang et al., 2007). For there to be proper homeostasis, there must be an
appropriate balance between anti- and pro-inflammatory cytokines, with some aiding in
immune cell response signaling and others acting as mediators to regulate the
inflammatory response and return the system to homeostasis. A loss of balance has been
well-described in the etiology of several diseases, including cancer, lung disease, and
osteoarthritis (Furman et al., 2019).
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Perhaps one of the most widely studied and influential cytokines in hemorrhagic
stroke is Interleukin-6 (IL-6). This cytokine is important for the initial development of
inflammatory response as well as the regulation of metabolic and regenerative processes
as inflammation resolves (Tanaka et al., 2014). As a result of the role it plays, increased
levels are associated with the development of ICH and aSAH, the severity of these
strokes, and complications after a stroke has occurred (Maas and Furie, 2009).
Correlation between increased IL-6 levels and poor patient outcomes post-aSAH and ICH
have also been noted in various studies (Chaudhry et al., 2017; Leasure et al., 2021).
Other specific cytokines have been noted for their anti-inflammatory responses.
For example, Interleukin-10 (IL-10) decreases the inflammatory response by inhibiting
lipopolysaccharide-induced glucose uptake and glycolysis, which then encourages
oxidative phosphorylation (Ip et al., 2017). As a result, an increase in IL-10 decreases
overall inflammation in the system and may protect vascular endothelium in the context
of stroke by counteracting some of the negative effects of excess inflammation (Garcia et
al., 2017).
Current Hemorrhagic Stroke Animal Models
Work in animal models of hemorrhagic stroke has demonstrated the
aforementioned inflammatory cytokine changes and suggested relationships between
certain cytokines, inflammatory responses, and disability status after the stroke event
(Ramiro et al., 2018). Yet despite the promise of these markers, the contributions of
cytokines in aSAH and ICH inflammatory response have not jumped the translational gap
to be tested for relevance in human patients. It is possible that the local and systemic
changes in cytokines may differ between animal models and humans, suggesting that
different mechanisms for inflammatory response are at play in these systems. But when
considering animal models of hemorrhage stroke, it is much more likely that there are
gaps in the ability to accurately produce the same conditions seen in humans versus
animals.
In the real world, a hallmark of hemorrhagic stroke is its sudden onset and
unpredictable course. In contrast, animal models must artificially induce such an event,
introducing additional variables that are not present in a naturally occurring event.
Various models introduce these to a greater or lesser degree; the most commonly used
animal models for aSAH and ICH are described in turn below. While all these models are
successful at showing some inflammatory effects, they are not completely accurate for
mimicking the actual physiological reaction that takes in the human brain—and the
reaction systemically—during the vascular event and early post-acute period. There is a
need for better and more representative models of vascular disruption.
aSAH single-blood-injection model
One common aSAH model is the single-blood-injection model, whereby blood is
injected directly into the subarachnoid space (Kamp et al., 2014). This model partially
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accounts for the perfusion of blood into the subarachnoid space, which would result in an
increase of pressure and damage to the surrounding tissue. However, from a mechanistic
perspective, there is no vascular rupture. Thus, from an inflammatory perspective, such
an injection would create a different environment relative to an aneurysm rupture. Due to
this inaccuracy, any cytokine change results (or generalized inflammatory results)
collected from this model may not be fully generalizable to the human subjects. Further,
this model does not account for the fluctuating perfusion of blood that can take place
during the aSAH event as bleeding, slowing, and rebleeding occurs in the hyperacute
period. This main downfall ignores this process, which is likely a major player in the
inflammatory response post-aSAH and a contributor to secondary complications.
aSAH endovascular puncture model
Another common model, the endovascular puncture model, is performed through
the insertion of a suture into the internal carotid artery and through to the circle of Willis.
At this point, the suture punctures the vessel wall (Kooijman et al., 2014). This
destruction of the vessel results in instantaneous bleeding into the subarachnoid space,
mimicking the aneurysm rupture that occurs in aSAH. While it may be mechanistically
similar to the human condition, the artificial condition is much more abrupt, with no
buildup of pressure inside the aneurysm and vascular wall. This sudden, rather than
progressive, nature of these events may result in different specific inflammatory
responses. When compared to the single-blood-injection model, this model better
replicates the mechanical action that occurs during aSAH. While it is not a spontaneous,
progressive rupture seen in humans, it does result in the destruction of a blood vessel and
the perfusion of blood into the subarachnoid space. Some differences in the inflammatory
response may occur due to the mechanical induction of this injury; however, such a
procedure most closely recreates the local inflammatory environment observed in aSAH.
Several animal models have also been established for ICH. These models provide
technical challenges in accessing and causing hematoma in deeper brain structures
without causing immediate mortality.
ICH single-blood-injection model
In contrast to the aSAH single-blood-injection model, this model injects blood
into the intracerebral space to create a hematoma, similar to what has been observed in
ICH. Still, as in the aSAH single-blood-injection model, there is again a similar
disadvantage that no vascular rupture is present.
ICH collagenase-injection model
On the other hand, the collagenase injection model results in the bursting of blood
vessels through the breaking down of collagen and the weakening of surrounding vessels.
In most cases, the collagenase injection method is carried out through the use of a
stereotactic apparatus to allow precise targeting. The exact brain area for the injection is
determined, and coordinates are used to inform the injection location. The needle
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containing the collagenase is then slowly lowered into the brain in order to ensure that no
mechanical damage is done to unrelated areas. The collagenase is then injected and the
needle withdrawn. By performing this precise injection technique, there are minimal offtarget effects, thus allowing for the creation of very replicable and specific hematoma
sites.
When comparing hematoma size, the single-blood-injection and the collagenase
injection models are similar. However, there are important differences between the two in
other factors. The damage caused by the collagenase injection results in greater
disruption of the BBB, increased neuron loss, increased tissue damage, an absence of
spontaneous neurological recovery, and the expansion of the hematoma over time when
compared to single-blood-injection (Jia et al., 2021). For all these reasons, the
collagenase model may be a more representative model for ICH in humans.
Aims
This dissertation aims to explore the inflammatory effects that occur in animal
models of hemorrhage stroke and compare these effects with those found in patient
samples. Our general premise for this work is that much of the information known about
the inflammatory environment post-hemorrhagic stroke has been gleaned from animal
models, which may be imperfect representations of the conditions found in hemorrhagic
stroke. These differences can greatly influence the translational abilities of potential
treatments that are tested in the models for clinical use in humans. In short, there is a gap
that must be filled to determine which model is the best mimic of the inflammatory
effects of hemorrhagic stroke in humans and is thus adequate for measuring and testing
anti-inflammatory treatments. The goal of this body of work was to definitively describe
the Inflammatory environment following hemorrhagic stroke, highlight the differences
between animal models and the human condition, and propose possible targets for
treatments that may be able to bridge the translational hurdles that face hemorrhagic
stroke research. These aims were investigated in multiple different projects.
The first project, described in Chapter 2, is a systematic review published in
Translational Stroke Research. This manuscript aimed to discover the breadth of the
literature on cytokine change and its role in the inflammatory response following aSAH.
Both animal models and human studies were considered in order to understand how
research in these areas fundamentally differed. Information such as the tissue type used,
the purpose of each study, cytokines investigated, and animal model utilized was
collected. Through systematic searching of electronic databases, important insights into
the current literature on the topic was collected and used to inform our projects moving
forward.
The second project, described in Chapter 3, investigated the inflammatory
environment found in rats after experimentally induced (endovascular puncture) aSAH
and humans who suffered the same condition. In humans, cytokine levels were measured
via cerebrospinal fluid (CSF) and plasma samples of aSAH patients collected at three
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different timepoints: post-rupture day 1-3, 4-6, and 7-9. The plasma was collected
intravenously, and the CSF samples were collected noninvasively from an external
ventriculostomy drain (a standard aSAH practice used to manage intracranial pressure
changes caused by aneurysm rupture). Rat cytokine levels directly after SAH were
compared to give an indication of the systemic and local inflammatory environment
surrounding the brain. The change over time and the absolute levels of cytokines
measured were used to better understand the inflammatory environment following aSAH
both locally (CSF) and systemically (plasma). Following aSAH, there was a particularly
significant increase in inflammatory cytokines IL-6 and IL-8. Further, these changes were
associated with demographic and clinical data to understand the overall role these
specific cytokines could possibly play in patient outcomes. Moving forward, these results
will establish commonly shared and significantly expressed cytokines, which will further
validate this rat model for aSAH.
The final project has been submitted to Neurochemistry International. This
project investigated ICH and its unique inflammatory environment. In particular, it
investigated the efficacy of a drug known as Verapamil on influencing the inflammatory
response, motor function, and cognitive ability following stroke. For this project, a mouse
collagenase model was utilized, brain samples were analyzed, behavioral tests were
conducted, and immune markers were measured. The project ultimately demonstrated
that Verapamil may have several beneficial effects on recovery following ICH.
The following chapters will explore each of these projects undertaken for the
completion of this dissertation. They aim to explore the available literature on the topic,
to discover possible mechanisms that can influence the inflammatory response, and to
compare the translational ability these animal models have in the actual human
phenomenon. The overall goal of this body of work is to better understand the
inflammatory environment post-hemorrhagic stroke to improve treatment and recovery.
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CHAPTER 2. A SYSTEMATIC REVIEW OF INFLAMMATORY CYTOKINE
CHANGES FOLLOWING ANEURYSMAL SUBARACHNOID HEMORRHAGE
IN ANIMAL MODELS AND HUMANS1
Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is a form of stroke that occurs
when a cerebral aneurysm ruptures and bleeds into the subarachnoid space surrounding
the brain. The incidence of new cases of aSAH in the United States is about 30,000/year
or 10/100,000 persons, accounting for ~5% of all strokes (’'Souza, 2015; Feigin et al.,
2003). Despite being a less-common form of stroke, aSAH accounts for about 40% of the
total number of stroke deaths nationally, and those who do survive often experience
severe long-term disability and reduced quality of life (Lantigua et al., 2015; Aisiku et al.,
2014). Mortality and morbidity rates are increased further for those patients who
experience cerebral vasospasm, a common complication that decreases cerebral blood
flow and can lead to delayed cerebral ischemia and secondary infarction. Inflammatory
dysregulation is thought to be a major determinant of these complications and poor
outcomes (van Lieshout et al., 2018). Thus, developing better treatment options requires
understanding the factors involved in pro-inflammatory immune response regulation and
disruption as they occur in the context of aneurysm rupture.
After the rupture of a brain aneurysm, neuroinflammation increases neural cell
death by interfering with endogenous repair mechanisms, acting through immune cells,
microglia, cytokines, chemokines, and other inflammatory molecules. Restoration of
immune homeostasis relies on proper regulation of T cells controlled by external signals,
such as those generated by cytokines. Cytokines are important signaling proteins vital for
inflammation and response to cellular damage, and individual cytokines can have pro- or
anti-inflammatory effects (Table 2-1). After aSAH, cytokine levels in brain tissue and
CSF increase in response to the rupture, indicating a rapidly changing inflammatory
response within the brain (Zeiler et al., 2017). Similar increases have been demonstrated
in blood plasma and serum, indicating systemic inflammatory processes are also altered.
Work in animal models has demonstrated persistent, longer-term inflammatory cytokine
change and suggested relationships between the neuro-specific and systemic
inflammatory effects, but many of these findings have yet to jump the translational gap to
be tested in the clinical arena. In this systematic review, we will describe the state of the
science in this area, considering animal models and aSAH patient samples. A secondary
goal of this review is to illuminate the translational hurdles that often arise between
animal experimental models and humans and how this affects this venue of aSAH
research. Finally, we suggest directions for future research in this area to fill these gaps.

Reprinted by permission from Springer Nature: Springer Nature. Translation Stroke Research. A
Systematic Review of Inflammatory Cytokine Changes Following Aneurysmal Subarachnoid Hemorrhage
in Animal Models and Humans. Devlin P, Ishrat T, Stanfill AG. (2022). https://doi.org/10.1007/s12975022-01001-y
1
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Table 2-1.

Main cytokines of interest.

Name
Interleukin-1
Interleukin-4
Interleukin-5
Interleukin-6
Interleukin-7
Interleukin-8
Interleukin-10
Interleukin-12
Interleukin-13
Interleukin-15
Interleukin-17
Interleukin-18
Interleukin-22
Interleukin-23
Interleukin-33
Tumor Necrosis Factor
Alpha
Interferon-Gamma
Transforming Growth
Factor Beta
Macrophage migration
inhibitory factor
Monocyte Chemoattractant
Protein-1

Symbol
IL-1 α/ β/R
IL-4
IL-5
IL-6
IL-7
IL-8
IL-10
IL-12
IL-13
IL-15
IL-17
IL-18
IL-22
IL-23
IL-33

Inflammatory Type
ProAntiX
X
X
X
X
X
X
X
X
X
X
X
X

TNF-α
IFN-γ

X

TGF-β

X

MIF

X

MCP-1

X

8

X
X

Methods
A systematic review of the literature was conducted by utilizing the following
three different databases: PubMed, SCOPUS, and the Cochrane Library. Our procedures
followed the established Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines (Moher et al., 2015). Three different search phrases were
established and applied to each of the three databases: “cytokines and subarachnoid
hemorrhage,” “cytokine levels and subarachnoid hemorrhage,” and “cytokine
measurement and subarachnoid hemorrhage.” Our inclusion criteria were: 1) written in
English; 2) published between January 2015 and September 2021; and 3) primary databased articles measuring changes for any cytokines in plasma, serum, CSF, and brain
tissue post-aSAH in either animal models and/or humans. For human studies, all
participants must have been 18 or older. For animal studies, the animals must be
representative of this age group (i.e., adults). There were no limitations on the animal
model species used. Review papers and meta-analyses were excluded.
Each search term combination was applied to each database, and an initial list of
possible articles was identified. From this list, duplicates were removed. Article titles and
abstracts were initially screened to determine adherence to inclusion/exclusion criteria.
Two authors independently reviewed this list, and any articles failing this test were
removed. Then, articles were separated into animal models or human subjects research,
and each set of articles were reviewed in full by these same two authors. Each individual
independently reviewed the list to ensure all inclusion/exclusion criteria were met; any
article not meeting criteria was then removed.
Results
Search Results
A total of 856 papers were returned from our selected databases. Of these,
duplicate papers across databases were removed. We then scanned titles and abstracts of
the remaining papers. Next, we removed papers for failing inclusion and exclusion
criteria in the title and/or abstract, leaving papers remaining for full text review. Of these,
95 used preclinical animal models, and 41 papers used specimens obtained from patients
during clinical care (Figure 2-1). Four papers used animal models and human samples
and were reported in both categories. These papers were then separated into animal
model and human studies. Publication dates and number of papers published from yearto-year between 2015-2021 varied over time (Figure 2-2).
Preclinical Animal Model Investigations
A total of 95 preclinical animal model studies are included in this review. These
studies analyzed cytokines for the following: illustrate the treatment effect of various
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Figure 2-1. Study selection flowchart for systematic literature search procedure
and outcomes.
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Figure 2-2. The change over time of articles being published in both human and
animal model studies.
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substances (n= 57); demonstrate cytokines’ relationship with other inflammatory factors
(n=36); serve as a biomarker for aSAH severity (n= 6); and show the change in cytokine
levels of the brain environment over time (n=8). The vast majority of included studies
(n=80) measured cytokine levels in brain tissue harvested post-mortem. The remainder
used blood serum (n=9) and CSF (n=11) as the tissue of choice, while only one utilized
plasma. Three different animal models were used in these projects, with most studies
using rats (n=67), a few using mice (n=22), and a handful using rabbits (n=6). The
aneurysm rupture model was performed most commonly by vascular puncture (n=55),
followed by blood or hemolysate injection or infusion (n=35), followed by blood clot
placement (n=21), extracranial-intracranial shunting (n=2), injection of enzymes (n=2)
and arterial occlusion (n=1). These studies were broadly representative of investigations
in pro- and anti-inflammatory cytokines, including the following: IL-1α, IL-1β, IL-4, IL6, IL-7, IL-8, IL-10, IL-17, IL-18, IL-22, IL-33, TNF-α, IFN-γ, and TGF-β (Appendix
A).
Individual cytokines have specific roles, either pro- or anti-inflammatory, and a
consideration of this differential effect was apparent throughout the preclinical work. For
example, three of the most prominent pro-inflammatory cytokines studied included IL-1β
(n=71), IL-6 (n=58), and TNF-α (n=75). Following aSAH, the levels of each of these proinflammatory cytokines were found to significantly increase across studies, with each of
them having varying behaviors depending on studies. They were thus most often used as
markers to show the anti-inflammatory nature of various substances. One report
demonstrated increases in IL-33 following injury, though other included studies did not
measure this change (Gong et al., 2018).
Another important cytokine being studied in this area is IL-10 (n=12). This
cytokine is well-established to act as an anti-inflammatory cytokine to dampen the
inflammatory response following injury. A few studies demonstrated that treatment of
aSAH (whether by the pharmaceuticals or use of stem cell therapeutics) was associated
with increases in the levels of IL-10 in conjunction with decreasing overall inflammation
indicated by changes of inflammatory cytokines IL-6, IL-1 β, and TNF-α (n=8).
Clinical Patient Investigations
A total of 41 clinical studies are included in this review. All human studies were
conducted on patients who had experienced an aSAH and consented to collection of
tissue samples themselves or via proxy. These studies focused on how cytokine change
serves as a biomarker for aSAH severity (n= 30); show how cytokine levels change over
time (n=16), investigate cytokines relationships with other inflammatory factors (n=14),
and illustrate the treatment effects of various substances (n=2). The majority of these
studies investigated cytokine levels in CSF (n=20) or in serum (n=22), while a few
considered alterations in blood plasma (n=8) or interstitial fluid (n=3). The included
studies investigated various specific cytokines, including the following: IL-1α, IL-1β, IL1R, IL-4, IL-5, IL-6, IL-7, IL-8 IL-10, IL-12, IL-13, IL-15, IL-17, IL-18, IL-23, IL-33,
TNF-α, IFN-γ, TGF-β, MIF, and MCP-1 (Appendix A). Clinical work revealed a high
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degree of concordance with the changes demonstrated in preclinical models. For
example, observed increases (from 1 to 14 days after injury) occurred in proinflammatory cytokines such as IL-1β (n=4), IL-6 (n=31), and TNF-α (n=14).
Capitalizing on the previous animal work mentioned [7], one study investigated changes
in IL-33 (Huang et al., 2015). As in the preclinical model, upregulation of IL-33 was
found post-aSAH. This upregulation of cytokine levels in IL-33, as well as in IL-17 (n=5)
and IL- 23 (n=1), were associated with clinical grading scales predicting poorer prognosis
(Chaudhry et al., 2017). The cytokine IL-33, in particular, has a strong relationship to
stroke severity scores following aSAH, whether considered from size of bleed on CT
scan (modified Fisher grading scale) or from clinical grading scale(s) (e.g., World
Federation of Neurological Surgeons Scale [WFNSS]). A few studies followed outcomes
longitudinally by measuring Glasgow Outcome Scale (GOS). Some measured outcomes
at 72 hours after rupture, while others followed the patients until 6 months post-stroke.
For these, increases in IL-33 concentration resulted in worse outcomes for patients
following aSAH (Gong et al., 2018).
Changes in the anti-inflammatory cytokine IL-10 were investigated in multiple
studies and found to be associated with worse outcomes. One study showed elevated
systemic IL-10 levels were found on day 7 post-aSAH in patients who suffered from
complications including cerebral vasospasm, nosocomial infections, or shunt-dependent
chronic hydrocephalus. Specifically, the data indicate that an increase in serum IL-10
levels on day 7 was able to predict chronic hydrocephalus and infections during the acute
treatment period of SAH (70% sensitivity and ~60% specificity for each complication).
This increase resulted in overall poorer outcomes, whether measured by modified Rankin
Scale (mRS) or GOS (Chaudhry et al., 2020). Another study showed that elevated
systemic IL-6 levels were a reliable biomarker for the development of common postaSAH complications that included seizures, vasospasm, and chronic hydrocephalus
(Chaudhry et al., 2017). Several other studies illustrated the correlation between changes
in specific cytokines and patient outcomes or comorbidities over several timepoints
following SAH (Table 2-2).
Changes in the pro-inflammatory cytokine IL-6 also influenced patient outcomes
(n=10). In one study, an increase in IL-6 and a decrease in IL-10 resulted in a poorer
functional outcome, as measured by mRS, at 3 months following aSAH (Ahn et al.,
2019). These results suggest a possible interrelated relationship between these cytokines
that may work to maintain the homeostatic balance of the inflammatory effects that may
influence common complications of aSAH, aSAH recovery, and long-term outcomes.
Discussion
This systematic review identified the state of what is known about cytokine
change in aSAH in preclinical and clinical work. Understanding the similarities and
differences in the results of these studies, as well as the knowledge gaps that are found,
will inform future research in this area and may identify targets for therapeutic
intervention.

13

Table 2-2.

Relationship between cytokine change and patient outcomes.

IL-23, IL-17

Sample Collection
Timeframe
(After aSAH)
Day 1 and 7

Timeframe
Patient Outcomes
Were Measured
Discharge

TNF-α, IL-6, IL-1R

Day 1

Discharge

Höllig et al., 2015

IL-6

Day 1

Schiefecker et al.,
2019

IL-6

2,8,12 hrs <24 hrs

IL-4, IL-6

Days 1-3, 5, 7 and 9

IL-6, IL-8, IL-10

Paper

Patient Outcomes

Associated Comorbidities

GOS and mRS (No
correlation)
GOS

-

Discharge and 6months after
Admittance and 3months

mRS

-

FGS
mRS

24 hr

Day 10 and 6months
Discharge

Linked to fever
Delayed Cerebral Infarction
Metabolic distress
Delayed ischemic
Neurological Deficit

IL-6
IL-6
IL-6

Days 1-5
≤ 48 hours of admission
Days 1, 4, 7, 10, and 14

3-months
Discharge
-

IL-6

Days 1-4

Discharge

Wu et al., 2016
Chaudhry et al.,
2020

IL-6, TNF-α
IL-10

Day 2
Day 1 and Day 7

Discharge
Discharge

Chaudhry et al.,
2017

IL-6

Days 1, 3, 5, 7, 9, 11, and
13

Discharge

HHS

Righy et al., 2018
Righy et al., 2018

IL-6 and IL-8
IL-4

Day 1, 2, 3
Day 1, 2,3

Day 7
Day 7

Mortality
Mortality

Gong et al., 2018

IL-33

Day 1

6 months

WFNSS
MFS
GOS

Chaudhry et al.,
2017
Wenneberg et al.,
2020

Al-Tamimi et al.,
2019
Savarraj et al., 2018
Helbok et al., 2015
Savarraj et al., 2018
Chamling et al.,
2017
Ďuriš et al., 2017

Cytokine of Interest
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HHS
mRS
mRS
HHS
GOS
HHS
HHS
mRS
GOS

-

Delayed Cerebral Ischemia
Global Cerebral Edema
Delayed Cerebral Ischemia
Cerebral Vasospasm
Infection
Cerebral Vasospasm
Chronic Hydrocephalus
Increasing Age
Seizures
Cerebral Vasospasm
Chronic Hydrocephalus
Pneumonia
-

Table 2-2.

(Continued).

Ridwan, Grote, and
Simon, 2021

IL-6

Sample Collection
Timeframe
(After aSAH)
Days 4 to 14

Lenski et al., 2017

IL-6

<24 hrs of EVD

-

-

Kao et al., 2015

IL-6

Days 0,1, and 2

Admittance and 1
month

Vlachogiannis et
al., 2019
Niwa et al., 2016

IL-6

Days 1, 4, and 10

-

GCS
FGS
mRS
-

IL-6

Day 1-14

3 months

GOS

-

Sheng-Yin Lv et
al., 2017

IL-1β, IL-18, TNF-α

Days 1-3, 4-6, and 7-9

Admittance and 6
months

Cerebral Edema
Cerebral Vasospasm

Chen et al., 2017

MIF

Day 1

Schiefecker et al.,
2017
Höllig et al., 2015

IL-6

every 24 hours

Admittance and 6
months
3 months

HHS
WFNSS
FGS
WFNSS
FGS
HHS

IL-6

Days 0, 1, 4, 7, 10 and 14

IL-1α, IL-2, IL-17,
TNFα
IL-6, IL-8, IL-10, and
TNF-α
IL-17A
MIF
IL-6 and IL-10

Day 3

Paper

Coulibaly et al.,
2020
Savarraj et al., 2017
Moraes et al., 2020
Yang et al., 2019
Zhong et al., 2017

Cytokine of Interest

Timeframe
Patient Outcomes
Were Measured
Admittance and
DischardeF

Patient Outcomes

Associated Comorbidities

FGS
mRS

Delayed Cerebral Infarction
Cerebral Vasospasm
External Ventricular Drain-Associated
Ventriculitis
Infection

-

Discharge and 6months
3 months

mRS

Intraparenchymal bleeding
-Deranged cerebral metabolism
-

mRS

-

Discharge

HHS

-

Discharge
Discharge

Mortality
HHS
GOS
HHS
MFS

Vasospasm
Delayed Cerebral Ischemia
-

Day 1, 2-4, 3-5 days, and
6-8
Day 1,2,3, 3+
Day 1
Day 1

Notes: HHS = Hunt Hess Scale, GOS = Glasgow Outcome Scale, FGS = Fisher Grading Scale, MFS = Modified Fisher Scale,
mRS = Modified Rankin Score, WFNSS = World Federation of Neurological Surgeons Scale.
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However, some limitations in the existing body of knowledge were found. There
were common limitations in the number of cytokines studied as well as few
investigations of the pro-/anti-inflammatory balance of said cytokines. Other gaps
identified were as follows: a paucity of information on how these cytokines relate to
long-term patient outcomes (with even fewer studies having clinically meaningful
longitudinal data in this regard); an absence of multi-tissue studies to allow comparison
of systemic and neuro-specific inflammatory responses; and methodological issues with
the representative preclinical aSAH induction models, with most included studies using
these animals as reservoirs to test pharmacological agents on inflammatory response
regulation. We will discuss each of these threads in turn. The overall nature of the
information published in these papers was compared to better understand the differences
between the inflammatory nature of human and animal model research being conducted
(Figure 2-3).
Scope of Cytokines Investigated and Pro-/Anti-Inflammatory Balance
Across species, the vast majority of studies (n=106) investigated only 4 out of all
possible cytokines: IL-1α, IL-1β, IL-6, and TNF-α. These cytokines are each well-known
as pro-inflammatory markers and therefore in the context of a recent aneurysm rupture
would generate the recruitment of T cells and trigger further immune system response
cascades (Dinarello, 2000; Kany et al., 2019). A failure to capture the full complement of
inflammatory response is myopic. The literature overwhelmingly demonstrates a lack of
consideration for the relative countering effects from anti-inflammatory factors (such as
IL-4, IL-8, IL-10, IL-12, and IL-13), which could just as easily influence the post-aSAH
environment as the pro-inflammatory markers more commonly studied. The balance of
pro- and anti-inflammatory effects of these cytokines is dynamic due to continuous
feedback from the immune system and localized responses in the injury area. In the
context of aSAH recovery, an understanding of the relative trajectory of this balance
remains important but not well-considered.
Furthermore, the balance between pro- and anti-inflammatory cytokines differs at
the molecular, organ, and whole-host levels (Cicchese et al., 2018). Similar questions
concerning this balance have been investigated in conditions such as generalized anxiety
spectrum disorder (GAD) and Multiple myeloma (MM). For example, patients with GAD
showed significantly higher ratios of TNF-α:IL10 and TNF-α: IL4 when compared to
control groups (Hou et al., 2017). In MM, researchers found that an unbalanced cytokine
system contributed to the condition and indicated that pro-inflammatory IL-6 and IL-1
play a role in tumor eradication (Musolino et al., 2017). This information suggests this
balance is a very important phenomenon in the development of inflammatory response
that creates disease phenotypes. Without full consideration of all relevant cytokines and
the relative16etabolionship of each, it is unclear how best to translate this information for
therapeutic benefit in patients. A better consideration of the broad range of cytokines,
with the measurement of counterplaying influences from multiple cytokine classes,
would more fully illustrate the inflammatory environment present, both systemically and
locally.
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Figure 2-3.
compared.

Key characteristics between human and animal studies
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Clinical Longitudinal Studies
Most research conducted on humans examined cytokine changes over time
relative to the rupture but not relative to specific patient outcomes, a fact that also limits
the translational capacity of the information (Bjerkne Wenneberg et al., 2021; Al-Tamimi
et al., 2019). In our included papers, however, specific cytokines were well-considered as
biomarkers of injury severity (Lenski et al., 2017; Ridwan et al., 2021; Kao et al., 2015).
Increases in these specific markers (e.g., IL-1β, IL-6, and TNF- α), particularly in the
acute (days) versus hyperacute (>24 hours) time period after initial injury, increased the
likelihood of a poor outcome, but such effect was largely related to associations with
stroke severity scores (Lv et al., 2018). This information underscores the deleterious
effects that increased inflammation can have following aSAH.
Still, there is an overall dearth of the literature that demonstrates how these
cytokines are associated with long-term recovery prognosis apart from just stroke
severity. Most studies simply measured cytokine levels at 2 or more hyperacute
timepoints (Roa et al., 2020; Gusdon et al., 2020). Long-term studies of cytokine change
post-stroke are typically tested at 7, 10, or 14 days following rupture. The longest-term
studies observed collected tissue 14 days after aSAH, but these studies were few (Niwa et
al., 2016; Höllig et al., 2015). A better understanding of the relationship between
cytokine changes and outcomes, as well as a better understanding of the longitudinal
trajectory of these changes, would place this information in context for clinical use.
Tissue Considerations
In addition, there is a lack of multi-tissue studies conducted in preclinical models,
so it becomes difficult to compare local neurological versus systemic response to rupture.
For example, the inflammatory response as seen in the CSF may be significantly different
than what is found in the brain tissue and blood following aSAH. In preclinical work,
multiple tissue samples are easily overcome, a boon that is largely not available in human
studies for ethical reasons. Although blood is easily collected and CSF may be collected
from a ventriculostomy drain (common in standard of care for these patients), there are
no studies that included post-mortem human brain tissue samples for analysis. When
comparing results from preclinical and human studies the tissue of origin must always be
taken into consideration, and this is one reason that a translation gap exists for preclinical
and clinical work in this area.
Pitfalls of Animal Models
Further, common aSAH rupture models used may not be appropriately
representative for the study of inflammatory response. The three most commonly used
animal models for aSAH include blood or hemolysate injection or infusion, blood clot
placement, and arterial puncture (Marbacher et al., 2019). Each model has its own pros
and cons. While all are successful at showing the effect of inflammation resulting from
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external forces creating a response in the brain, they are not accurate at mimicking the
actual mechanical actions that take place during spontaneous vessel rupture, as what
occurs during aSAH.
For example, the second most common model is the blood-injection aSAH model
whereby blood is injected directly into the SAH space (Kamp et al., 2014). From an
inflammatory perspective, external injection would create a different environment
relative to an aneurysm rupturing from a blood vessel. Consequently, the cytokine change
results generated from this model may not be fully generalizable to human subjects. This
model also does not account for the ongoing perfusion of blood into the SAH space that
would result in subsequent increases in intracranial pressure and further damage to the
surrounding tissue.
Of the models represented in our review, the arterial puncture model may be the
best for accurate recreation of what is seen in humans. While this model is still not a
spontaneous rupture, it results in the destruction of a blood vessel and the ongoing
perfusion of blood into the SAH space. Still, there may remain some differences in the
inflammatory response due to the mechanical induction of this injury. Better and more
representative models of vascular disruption should continue to be developed.
Cytokine Change as a Marker for Treatment Effectiveness
In general, most included preclinical studies utilized cytokine levels as a means to
illustrate inflammatory response, with many considering the cytokine change alterations
relative to pharmacologic administration (Wei et al., 2017; Zhang et al., 2016; Tu et al.,
2018; Li and Han, 2018). In these studies, researchers often considered specific proteins
of interest and only used cytokines for additional information regarding overall
inflammatory profiles. Largely, the preclinical animal model work focused on cytokine
change in response to the pharmacological action of drugs. Rolipram, rutin, and
salvianolic acid administration all produced decreases in TNF-ɑ, IL-6, and IL-1β (Hao et
al., 2016; Gu et al., 2017; Peng et al., 2018). However, each therapeutic achieved this
response in different ways. Rolipram worked by regulating the SIRT1 (Sirtuin 1)/NF-κB
pathway, rutin by regulating the RAGE (receptor for advanced glycation end product)–NF-κB pathway, and solvianolic acid by influencing ERK/P38/NRF2 signaling. In these
studies, the three mentioned cytokines were used as markers for inflammation to better
inform how these drugs work on influencing the signaling pathways involved in their
production.
Behavioral assessment of outcomes and their relationship to cytokine changes
were also utilized in these studies. Most animal studies relied on changes in modified
neurobehavioral scores such as the modified Garcia score to measure how specific
treatments improved outcomes following SAH (Tu et al., 2018; Liu et al., 2019). While
others used more specialized tools, such as Morris water maze and rotarod performance
tests, to see how treatments improved memory and motor function (Wang et al., 2020;
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Zhang et al., 2020), the robustness and selection of these behavioral measures often
depended on the exact questions the researchers were trying to answer.
The translational potential of this work is limited without first knowing the
longitudinal effects of these pharmacologics on the relative pro-/anti-inflammatory
balance that would produce optimal patient outcomes. In addition to these considerations,
further preclinical studies specifically designed to inform how environmental factors
(such as pre-stroke diet, fitness, and stress levels) affect the inflammatory pathways
following aSAH would be very valuable.
Summary
Overall, there is a need for more research that focuses on cytokine changes across
tissues and specifically how they can relate to outcomes and recovery following aSAH.
Further, there remains a need for comprehensive research investigating the whole
complement of cytokines to better understand the inflammatory environment post-aSAH.
This includes considerations of the relationship between anti- and pro-inflammatory
cytokines following injury. Animal models should be thoroughly considered for their
limitations in translational capabilities for human subjects and for their acumen in
accurately representing aneurysm rupture conditions. By conducting more comparative
and controlled research, the translational gap between human and animal studies may be
closed, allowing for the development of better treatments and improved outcomes for
these patients.
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CHAPTER 3. A COMPARATIVE STUDY OF THE INFLAMMATORY
ENVIRONMENT FOLLOWING ANEURYSMAL SUBARACHNOID
HEMORRHAGE
Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is a dangerous form of stroke
resulting from the rupture of an aneurysm that subsequently releases blood into the SAH
space surrounding the brain. This release of blood results in inflammation and increased
intracranial pressure, pressure that in turn causes further inflammatory cascades and the
death of brain tissue —all major contributors to the high mortality and morbidity rates
seen in this clinical population. After aSAH, the rapid increase in inflammation can lead
to the development of detrimental secondary effects such as vasospasm, delayed cerebral
ischemia, and secondary infarction. A better understanding of the inflammatory response,
and the trajectory of that response during stroke recovery, has the promise to help guide
treatment decisions and the development of future therapeutics.
In response to any injury, the immune system releases small molecules called
cytokines to recruit immune cell activation. The balance of cytokines is dynamic due to
continuous feedback from the immune system and localized responses in the area of the
injury. Furthermore, the composition of the cytokine complement differs at the
molecular, organ, and whole-host (i.e., systemic) levels (Kany, Vollrath, and Relja, 2019;
Geginat et al., 2016; Cicchese et al., 2018). It is likely that unregulated balance of
specific cytokines may play a role in the development of the secondary clinical sequelae
post-aSAH; the trajectory of these changes may also play a role. Thus, a greater
understanding of how these cytokines change over time and the relative levels of each
cytokine (both systemically and locally) following aSAH are key pieces of information
that are needed before these changes can be targeted in therapeutic interventions.
Pre-clinical animal models are commonly used for this type of inquiry. The two
main types of animal models utilized for these experiments are the aSAH single/doubleblood-injection model and the aSAH endovascular puncture model. The aSAH singleblood-injection model is generated by the direct injection of blood into the SAH space
(Kamp et al., 2014; Lee et al., 2008; Jackowski et al., 1990). An advantage here is that an
increase in intracranial pressure is observed; however, this does not recreate the
inflammatory environment post-aneurysm rupture.
Possibly better for the measurement of the neuroinflammatory environment, the
second model involves the mechanical puncturing of a blood vessel within or around the
brain (Bederson et al., 1995; Höllig et al., 2015; Leclerc et al., 2018). This results in the
destruction of a blood vessel that release blood into the SAH space, as is observed in
humans with aSAH. It is from these models that interleukin-1β (IL-1β) has begun to be
tested as a therapeutic target (Dinarello, 2018; Rothwell & Luheshi, 2000; Viana-Huete
& Fuster, 2019; Lopez-Castejon & Brough, 2011). Yet, despite promise in animal
models, many therapeutic trials have historically failed to jump the translational gap for
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successful application in the human patient. One reason may be that these artificially
created models may not fully represent the inflammatory environment that is seen in the
human condition, as there is a dearth of side-by-side comparisons across species. The
lack of data is especially noticeable when comparing the localized neuroinflammatory
environment (i.e., CSF and brain samples) with the systemic inflammatory environment
(i.e., blood) that is more easily accessible and thus may be most appropriate for
measurement in clinical practice.
Here, we aimed to address this gap. Using an endovascular puncture model of
aSAH in rats, we compared cytokine results in CSF and blood serum to those obtained in
the same tissues taken from human aSAH patients. These direct comparisons allow a
better understanding of how well this animal model represents the actual inflammatory
environment observed in humans. We also explored the trajectory of cytokine change
over time in our human samples. These results will help future work navigate that
translational gap to improve post-aSAH outcomes.
Methods
Animal Model of aSAH
Sample
A total of 10 laboratory-grade Wistar rats (Charles rivers) were used. These
animals were adult males with an average weight of 402 grams. Animals were housed in
UTHSC’s rodent animal facility and monitored by veterinary staff under standard
conditions (temperature 21–25 °C, humidity 45–50%) on a 12:12 h light-dark cycle with
ad lib access to standard food and water. All American Association for Laboratory
Animal Science (AALAS) and institutional (IACUC) safety guidelines were followed
throughout this experiment (UTHSC IACUC approval # 20-0138).
Experimental procedures, biospecimen collection, and handling
A sham procedure was conducted (n=4) or aSAH was experimentally induced
(n=6) when rats were 12 weeks in age (equivalent to middle-aged adults, a typical time of
onset of aSAH in human patients). All rats were first anesthetized (Isoflurane) and placed
on a surgical platform with a heating pad to maintain body temperature. The rat’s necks
were then shaved, and the right internal carotid artery was surgically exposed. In the
sham group, the carotid artery was then sutured closed. The aSAH group of rats
underwent surgery following the procedures outlined in the Sheffield Model of
Subarachnoid Hemorrhage (Veelken et al., 1995). Briefly, a nylon suture was inserted up
the internal carotid artery until it reached the Circle of Willis. Once there, the suture was
pushed forward, piercing a hole in the right anterior cerebral artery, resulting in a bleed in
the ventral portion of the brain, a phenomenon similar to aSAH. Both sham and aSAH
rats were then sutured closed and injected with 2 ml of Lactated Ringer’s saline solution
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subcutaneously at the scruff of the neck. All rats were then allowed to recover under a
heating lamp. Upon transfer back to their cage, a nutritional gel was provided to ease
recovery. After 24 hours, all animals were humanely euthanized following all
institutional guidelines and the IACUC-approved protocol. Samples of CSF and plasma
were then collected postmortem in both aSAH and sham groups. CSF was collected by
carefully inserting an 18-gauge needle connected to surgical tubing and a syringe into the
cisterna magna. A technique similar to this was previously established in mice but was
adapted here for use in our rats (Lim et al., 2018). CSF samples were then centrifuged,
and the supernatant was collected for further analysis. Blood was collected from the heart
using a syringe, placed in an EDTA tube, and separated by centrifuge into plasma and
buffy coat. All samples were then placed in long-term storage at -80°C until data
analysis.
aSAH Clinical Samples
Sample and setting
This portion of the study capitalizes on the enrollment of a larger, longitudinal,
and observational study of outcomes after aSAH that enrolled patients at the time of
hospitalization for aSAH. Patients were screened for potential inclusion by the attending
neurologist involved in their care at Methodist University Hospital. Inclusion criteria
included: males and females over the age of 18, diagnosis of aSAH confirmed by
angiography, Hunt/Hess grade greater than or equal to 2 and/or Fisher score greater than
or equal to 3, and English-speaking. Patients were excluded for the presence of previous
neurological disorders (including prior stroke), sepsis, or infectious or preexisting
inflammatory disease that may affect cytokine levels and confound results. Pregnant
women were excluded, as this may have confounded cytokine levels analysis through
fetal circulation; patients with a history of blood transfusion within the previous 12 weeks
were excluded for similar reasons. The attending neurologist involved in their care
obtained verbal consent to be approached by research personnel who provided risks and
benefits of participation and obtained informed consent from the patient or legally
authorized representative. Demographic and clinical data were obtained from the
electronic medical record, including age, race, sex, weight, height, treatment method,
prior medical history, medications, comorbidities prior to aSAH, admission Glasgow
Coma Scale (GCS) Score, Fisher score, and Hunt/Hess Grade. Blood samples were
obtained via standard venipuncture by drawing an additional tube at the time of routine
clinical blood draws. CSF was obtained noninvasively via an external ventriculostomy
drain. This protocol was approved by the Institutional Review Board of the University of
Tennessee Health Science Center, #15-03974-FB.
Biospecimen collection and handling
Both blood and CSF specimens were collected between 0400 and 0700 across 3
different timepoints in the acute recovery period (Days 1-3, 4-6, 7-9). After collection,
the samples were placed on ice and transported to the laboratory. At the lab, the blood

23

and CSF were centrifuged and processed in a similar manner to the rat samples above.
These components were also placed in long-term storage at -80°C until further analysis.
Measurement of Cytokine Levels
In both rat and human samples, measurement of the cytokine levels in the tissues
was carried out using an ELISA-based multiplex assay run on a MESO QuickPlex
SQ120. This machine is a high-quality, enzyme-linked immunosorbent assay instrument
that allows multiplexing of cytokine markers with a rapid 90-second runtime on 96-well
plates. Premade panels are commercially available for this instrument to multiplex for the
detection of several different types of cytokines. For the rat samples, the V-PLEX
Proinflammatory Panel 2 Rat Kit (Cat No. K15059D-1) was utilized. This panel analyzed
levels of FN-γ, IL-1β, IL-4, IL-5, IL-6, KC/GRO, IL-10, IL-13, and TNF-α. Note that
multiple studies have shown that KC/GRO, a chemoattractant for neutrophils, serves as a
related protein and representative marker for IL-8 in rodent samples (Dunstan et al.,
1996; Shiratori et al., 1994; Merz et al., 2003). These cross-sectional results were then
compared to that of the human samples as described below.
For the human experiment, the panel was a custom UPLEX Panel developed to
measure known neuroinflammatory biomarkers in human plasma and CSF. Similar
assays have been successfully utilized in a range of several prior studies. These include
investigations that range from the effect of cytokines in the development of Alzheimer’s
disease and glaucoma to the role they play in chronic traumatic encephalopathy (Cherry
et al., 2017; Gupta et al., 2017). The cytokines measured on our panel included IL-1β,
IL-4, IL-6, IL-8, IL-10, IL-17A, IL-33, and TNF-α. For the human samples, all three
timepoints were run and the results collected. The resultant cytokine levels were assessed
by timepoint and then compared over time within and between subjects for associations
with clinical and demographic characteristics.
All samples for this project were prepared in duplicate to allow for technical and
biological replicates. Built-in quality controls are included in the assay plates for each
marker.
Statistical Analysis
The software program MSD Discovery Workbench 4.0.13 was utilized to extract
and analyze the raw cytokine levels collected by the MESO QuickPlex SQ 120
instrument. For clarity in the description of these studies, those cytokines that were
tested, but which were not present/were undetectable in any of these samples, were not
reported on in this article (this excludes FN-γ, IL-5, IL-13, IL-17A, & IL-33). After
removing those cytokines, the raw data were exported for additional statistical analyses
conducted using R statistical software, version R-4.1.2 (Ihaka & Gentleman, 1996;
Ripley, 2001). In rats, two-sample t-tests compared results between the sham and aSAH
groups. For the human group, absolute cytokine levels were measured as well as the
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trajectories across the timepoints. The means, standard deviations, and univariate
associations for clinical and demographic factors were considered. The cytokine levels
were then modeled in robust linear regression, with demographic/clinical variables
serving as predictors. All tests were two-sided, and statistical significance was set at a p
value of less than or equal to .05 without any multiple testing adjustment.
Results
Animal Model Results
In the rat model of aSAH, cytokine levels between CSF and plasma were
qualitatively similar. In both tissues, levels of IL-6 and KC/GRO were significantly
(p<0.05) higher than all other cytokines. In the CSF, KC/GRO was present at a
concentration of 93.89 pg/ml, while IL-6 was present at a concentration of 76.55 pg/ml.
These are 4.3 and 3.5 times larger, respectively, than the next most present cytokine, IL10 (21.72 pg/ml); the remaining cytokines were present at ~1/2 to 1/3 of this lower
concentration (Figure 3-1a). In rats, the inflammatory environment in CSF appears to be
more diverse than that in plasma; IL-4 and IL-1β were present in CSF samples but were
not detected in our plasma samples. The remaining cytokines were present in plasma,
with KC/GRO at the highest concentration (95.97 pg/ml) and IL-6 present at 78.33 pg/ml.
TNF-α was present at low levels in the plasma samples (3.29 pg/ml) (Figure 3-1b).
When comparing the differences in cytokine levels between the sham and aSAH
rats, some differences were observed. Specifically, average KC/GRO levels in the CSF of
aSAH rats (93.89 pg/ml) were significantly higher than that of sham rats (43.88 pg/ml,
p=0.013). A similar phenomenon was observed in the IL-6 CSF levels of aSAH rats
(76.55 pg/ml) compared to sham rats (40.46 pg/ml), though this result was nonsignificant
(p=0.392) (Table 3-1).
Human Results
Demographic and clinical information
Our 13 subjects were an average of 52 years old (IQR: 49~58), 54% African
American, and 54% female with a median Hunt/Hess Grade 3 and Fisher score 4.
Average BMI was 31.77, and about half were smokers (53.85%). Over half the sample
had been diagnosed with cardiac disease prior to the aSAH (53.85%); nearly half had
some form of pulmonary disease (46.15%); and roughly a third had a prior history of
other neurological disease (30.77%), diabetes (30.77%), or gastrointestinal disease
(38.46%) (Table 3-2).
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Figure 3-1.
surgery.

The average cytokine concentrations in rats following aSAH
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Table 3-1.

Comparison of SHAM and SAH model cytokine concentrations.
Sample Cytokine
CSF

Plasma

IL-6

Mean_ Mean_
SAH
Sham
76.55
40.46

t

d.f.

P Value

1.01

2.83

0.3928

5

0.0134

KC/GRO

93.89

43.88

3.74

IL-1ß

3.95

4.98

-0.78 1.86

0.5214

IL-6

78.33

129.05

-1.83 5.99

0.1168

KC/GRO

95.97

101.42

-0.06 6.41

0.9533

TNF-a

3.25

2.96

0.39

0.7103

6.66

Notes: CSF= Cerebrospinal fluid, SAH= Subarachnoid Hemorrhage, d.f.= degrees of
freedom.
Table 3-2.

Demographics of the study cohort.

Characteristic
Age
Sex

Levels

N (%) or Median (IQR)
52 (49~58)
Female
7 (53.85%)
Male
6 (46.15%)
BMI
31.77 (19.13~39.54)
BMI category
Normal Weight
3 (23.08%)
Obese
7 (53.85%)
Underweight
3 (23.08%)
Race
African American
7 (53.85%)
Caucasian
6 (46.15%)
Fisher Score
3
4 (30.77%)
4
9 (69.23%)
Hunt Hess Grade
2
5 (38.46%)
3
7 (53.85%)
4
1 (7.69%)
Prior history of cardiac disease
No
6 (46.15%)
Yes
7 (53.85%)
Prior history of pulmonary disease
No
7 (53.85%)
Yes
6 (46.15%)
Prior history of neurological disease
No
9 (69.23%)
Yes
4 (30.77%)
Diabetes
No
9 (69.23%)
Yes
4 (30.77%)
Gastrointestinal disease
No
8 (61.54%)
Yes
5 (38.46%)
Smoking history
No
6 (46.15%)
Yes
7 (53.85%)

Notes: IQR= Interquartile range, BMI = body mass index.
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Human cytokine levels
As in rats, IL-6 and IL-8 levels were significantly higher than all other cytokines
in both tissues (p<0.05). In CSF, IL-8 was the most present in our sample (1022.89
pg/ml) followed by IL-6 (745.87 pg/ml) (Figure 3-2a). The next most present cytokines
in our samples were at much lower concentrations (IL-1β=3.97 pg/ml and TNF-α=2.29
pg/ml). Similar average relative concentrations were also seen in plasma (IL-6=8.65
pg/ml, IL-8=7.86 pg/ml, TNF-α=1.47 pg/ml; Figure 3-2b). When compared for
concentrations across tissues, the concentration levels of IL-1β, IL-6, and IL-8 were
significantly higher in CSF as compared to plasma (p<0.001). IL-10, IL-4, and TNF-α
were not significantly different across tissues (p >0.05) (Table 3-3).
Trajectory of human cytokine levels following aSAH
Cytokine levels were also assessed for changes over time across three timepoints
in both tissues. IL-10 showed significant decreases in levels over time in CSF (β=-0.57,
p= 0.007). IL-6 and TNF-α showed a similar downward trend, but this was not
statistically significant (Table 3-4). Conversely, in plasma, levels of TNF-a (p= 0.008)
were found to increase over time, with the observed differences between timepoint 1 to 3
being quite marked (p= 0.017) (Table 3-5).
Across both tissues, IL-8 appears to have the largest and most consistent increase
following aSAH (Figure 3-2). However, this trajectory did not reach significance for
either tissue. Still, in plasma, comparisons of timepoint 1 to 2 and timepoint 1 to 3 both
reached significance (p=0.037 and p= 0.008, respectively).
Association of cytokine levels with demographic and clinical factors
The association of various cytokines with patient demographics and clinical
factors was then analyzed. In CSF, cytokine change was associated with the demographic
factors of age, race, and sex (Table 3-6). Older age was associated with cytokines IL-1β
(p= 0.035), IL-6 (p= 0.063), and IL-8 (p= 0.041). TNF-α (p= 0.039) and IL-4 (p= 0.036)
cytokine levels were associated with male sex, while stroke severity as measured by
Fisher Scale was found to be associated with IL-1β (p= 0.021) and TNF-α (p= 0.009)
levels. Lastly, higher levels of IL-1β (p= 0.029) were seen in Caucasian patients.
Interestingly, in plasma, the tested cytokines were often associated with prior
medical history such as: diabetes (IL-8, p= 0.040), smoking (IL-8 p= 0.027), history of
pulmonary disease (IL-4, p= 0.013; and IL-6, p= 0.061), and history of gastrointestinal
disease (TNF-α, p= 0.016) (Table 3-7). In plasma, higher BMI was also found to be
associated with IL-10 (p= 0.0066).
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Figure 3-2.
aSAH.

The average cytokine concentrations over time in patients following
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Table 3-3.
aSAH.

Comparison of cytokine levels of plasma versus CSF in patients after
Cytokine Estimate
CI95
IL-10
0.274
-0.21 ~ 0.757
IL-1ß
-2.523
-2.989 ~ -2.058
IL-4
0.044
-0.361 ~ 0.45
IL-6
-3.866
-4.491 ~ -3.241
IL-8
-4.464
-4.89 ~ -4.038
TNF-a
0.089
-0.256 ~ 0.433

Table 3-4.

P Value
0.2714
0.00001
0.8309
0.00001
0.00001
0.6157

Time trend changes after aSAH in CSF.
Cytokine Estimate
CI95
P Value
IL-10
-0.574
-0.952 ~ -0.195 0.0066
IL-1ß
0.137
-0.264 ~ 0.537 0.5095
IL-6
-0.210
-0.775 ~ 0.356 0.4744
IL-8
0.199
-0.247 ~ 0.645 0.3903
TNF-a
-0.353
-0.736 ~ 0.03
0.0828
IL-4
0.215
-0.109 ~ 0.54
0.2073

Table 3-5.

Time trend changes after aSAH in plasma.
Cytokine Estimate
CI95
P Value
IL-10
0.179
-0.036 ~ 0.393 0.1152
IL-1ß
0.048
-0.292 ~ 0.389 0.7830
IL-4
0.000
-0.353 ~ 0.352 0.7830
IL-6
-0.222
-0.516 ~ 0.072 0.9979
IL-8
0.255
0.082 ~ 0.427 0.1509
TNF-a
0.113
0.026 ~ 0.199 0.0079
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Table 3-6.

Association of patient cytokine levels with clinical factors in CSF.

Cytokine Clinical Factor Change
CI95
P Value
IL-1β
Age
0.034
0.003 ~ 0.064 0.0354
IL-1β
Race
0.721
0.097 ~ 1.344 0.0294
IL-1β
Fisher
-0.824 -1.492 ~ -0.156 0.0206
IL-6
Age
0.075
0.004 ~ 0.145 0.0631
IL-8
Age
0.05
0.008 ~ 0.093 0.0408
TNF-α
Sex
-0.685 -1.314 ~ -0.057 0.0391
TNF-α
Fisher
-0.916 -1.572 ~ -0.261 0.0094
IL-4
Sex
-0.579 -1.084 ~ -0.074 0.0357

Table 3-7.

Association of patient cytokine levels to clinical factors in plasma.

Cytokine Clinical Factor Change
CI95
P Value
TNF-α
GI
-0.462 -0.782 ~ -0.142 0.0163
IL-8
Smoking
0.436
0.102 ~ 0.77
0.0265
IL-8
Diabetes
-0.444 -0.816 ~ -0.071 0.0395
IL-6
Pulmonary
0.905
0.054 ~ 1.757 0.0612
IL-4
Pulmonary
-0.727 -1.271 ~ -0.184 0.0137
IL-10
BMI
0.04
0.017 ~ 0.064 0.0066
Notes: GI = gastrointestinal, BMI = body mass index.
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Discussion
The overall goal of our research was to better understand the inflammatory
response that takes place following aSAH. In this project at hand, we elected to
investigate cytokine change due to these molecules’ important role in immune cell
recruitment and signaling. Along the same lines, we utilized two different tissue types,
CSF and plasma, to better characterize the inflammatory response locally and
systemically. Overall, our results suggest that the aSAH inflammatory response in rats is
similar both systemically and localized. Humans show a diverse cytokine environment in
both tissues, with the largest concentration of cytokines being found in the localized
environment obtained from CSF.
We conducted our investigations in both rat models and human subjects to better
understand the differences between these species and how they may impact the
translation of results found in animal models for improving treatment for human patients.
Across species, the two cytokines with the highest concentrations were IL-6 and IL-8
(KC/GRO in rats). An interesting result in human samples was that while the CSF levels
of IL-6 and IL-8 were significantly higher than what was found in plasma, the levels of
TNF-a, IL-1β, IL-4, and IL-10 were similar across both tissues. This suggests the
cytokines IL-6 and IL-8 could play a greater role in regulating the localized inflammatory
response, relative to the other cytokines.
Role of IL-6
IL-6 is a well-established, pro-inflammatory cytokine. It is secreted by
osteoblasts, serves as a myokine, and is secreted by macrophages (Nara & Watanabe,
2021). Unsurprisingly, it has been found to stimulate the inflammatory response in
conditions such as diabetes, Alzheimer’s disease, atherosclerosis, and intracerebral
hemorrhage (Dayhoff-Brannigan et al., 2008; Wright et al., 2006; Leasure et al., 2021).
However, IL-6 has also been shown to control local and systemic anti-inflammatory
responses, as it has been found to stimulate the production of IL-1 receptor antagonists
and activate STAT3 (in models of cancer), both of which are anti-inflammatory
mediators (Gabay, 2006; Scheller et al., 2011). Here, this cytokine may play a
multifaceted role. After aSAH, several other organ systems are affected in the aftermath
of rupture, requiring a system-wide inflammatory response. This generalized oxidative
stress may be one of the reasons why we see such an increase in this particular cytokine.
Role of IL-8 (KC/GRO)
The cytokine IL-8 also plays an important role in the inflammatory response by
inducing a local, large, and long-lasting accumulation of neutrophils to the site of damage
(Bernhard et al., 2021; Harada et al., 1994). These neutrophils play an important role in
stroke recovery following ischemic stroke where they can result in the elevation of
cerebral edema, brain injury, and blood-brain barrier disruption (Jickling et al., 2015).
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Here, our results indicate that elevations in IL-8 may serve a similar role in aSAH.
Additionally, it has been found that elevated levels of IL-8 are seen in patients with
diabetes and in those who have a history of smoking (Cimini et al., 2017; Mio et al.,
1997). Our results here are consistent with this previous work. These risk factors that
contribute to aSAH onset, in turn may also contribute to the dysregulated inflammatory
response that is observed after aneurysm rupture. Lastly, our study was able to show that
there was a significant difference for KC/GRO levels in CSF between the sham and
aSAH surgery groups of rats. This illustrates, that the surgery does produce a similar
inflammatory response to aSAH in vivo.
Change in Cytokine Levels Over Time
Three of our investigated cytokines (IL-10, IL-8, and TNF-a) demonstrated
change over time, with all fluctuating over the course of the first nine days post-rupture in
aSAH patients. It is known from the literature that IL-10 is an anti-inflammatory cytokine
that is important for controlling the inflammatory response. In our human CSF samples,
we observed a significant decrease of IL-10 over time (Figure 3-2a). This illustrates that
after aSAH, there is most likely an increase in localized inflammatory response that can
be measured in the CSF. In other words, in response to the hemodynamic disturbances
and tissue damage taking place, the immune system responds by decreasing the levels of
IL-10 in the localized area of rupture. Supporting this thought, it has been found that
increased levels of IL-10 can negatively affect the response to associated hemodynamic
disturbances and tissue damage (Iyer & Cheng, 2012).
In plasma, we observed a consistent increase of IL-8 and TNF-a over time. As
previously discussed, IL-8 is responsible for neutrophil response and recruitment. So,
because of aSAH disturbance, pro-inflammatory IL-8 levels increased over time,
compensating for the dysregulation. On the other hand, TNF-a is released by
macrophages and plays an important role in systemic inflammatory response that
involves pro-apoptotic and pro-inflammatory signaling cascades (Parameswaran & Patial,
2010). In our patients, this release takes place system-wide in the plasma in response to
aSAH onset in order to induce appropriate inflammatory response. IL-8 and TNF-a are
both proinflammatory and increase over time. This increase is appropriate and expected,
given the roles we know these two cytokines play in inflammatory regulation. The
specific cytokine changes that we have observed in our tissues are consistent with the
roles we know these cytokines play in other conditions. Likewise, the change trajectory
we have observed following aSAH is consistent with the role we know they play in
systemic circulation.
Cytokine Change Associated with Clinical and Demographic Factors
Our results also show that cytokine levels and inflammatory response are
associated with several other demographic and clinical factors. Past medical conditions,
age, sex, and race can all influence the inflammatory response. Inflammatory conditions,
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such as a history of smoking, pulmonary disease, gastrointestinal disease, obesity, and
diabetes were associated with both absolute cytokine levels and change over time in our
human samples, both in CSF and in plasma. These results are consistent with the other
literature on the topic and may not reflect associations with only the aSAH condition
itself. For example, TNF-a has been found to play an important role in gut-related
diseases and intestinal homeostasis (Ruder et al., 2019) while low IL-10 levels have been
found to be associated with metabolic syndrome in obese women (Esposito et al., 2003).
Such preexisting conditions may alter cytokine levels and change, both within the context
of aSAH and independent of its effects.
Alternatively, we found that cytokine levels in CSF were relative to demographic
factors such as age, sex, and race. This association may be one possible biological
correlate of the demographic associations with mortality and morbidity rates for this
clinical group. For example, both IL-1ß and IL-6 levels have been previously shown to be
predictors of poor outcomes following ischemic stroke (Shaafi et al., 2014; Sobowale et
al., 2016). Taken together, the specific cytokines and their levels, along with other
clinical and biological factors, may someday serve as predictive markers for recovery
outcomes post-aSAH.
Translational Implications
Taken together, our results paint an interesting picture for the translational
implications of this work. First, they illustrate that shared cytokines may be drivers of the
inflammatory response following aSAH. In both species, IL-6 and IL-8 (KC/GRO) were
shown to be the principal cytokines present. However, there appears to be a difference in
the levels and characteristics of inflammatory response in the different tissues. In
humans, the response seems to be more localized to the CSF, while in the rat models, the
response was more mixed in nature. This could be due to unique genetic differences,
differences in leukocyte composition, difference in size between rats and humans, or the
surgical aSAH model itself.
Lastly, the difference could also be due to any anti-inflammatory treatments given
to patients during hospitalization. Many of these treatments are not able to cross the BBB,
and most are not given via the intrathecal route. As a result, systemic inflammation is
controlled while localized inflammation continues. This could potentially have altered
our results.
However, our results have interesting translational implications overall. It appears
that IL-6 and IL-8 (KC/GRO) behave similarly in both species and can be possibly
targeted for future treatment development. For example, one animal study showed that
administration of a novel selective proinflammatory cytokine inhibitor (CNI-1493)
decreased IL-6 levels and reduced the likelihood of vasospasm post-aSAH (Bowman et
al., 2006). It reasons that such inhibitors may also be used to reduce other secondary
sequelae, and these may improve recovery outcomes. However, such therapies may have
marked off-target effects, and much research remains to be done.
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Conclusions
Our study illustrates that the inflammatory environment present following aSAH
is primarily modulated by cytokines IL-6 and IL-8, though other several other cytokines
are also present in lower levels. It appears that the inflammatory environment of both rats
and humans is similar while there are specific differences that arise across the two tissues
examined here.
Despite our interesting results, there remains a need for more research in this area.
Specific areas for inquiry include further information on cytokine changes across tissues
along with more detailed information about how these changes relate patient outcomes
and recovery following aSAH. This includes considerations of the relationship between
and balance of anti- and pro-inflammatory cytokines following aneurysm rupture. In such
work, animal models should be critically examined for their limitations in translational
capabilities for human subjects and for their acumen in accurately representing aneurysm
rupture conditions.
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CHAPTER 4. VERAPAMIL INHIBITS TXNIP-NLRP3 INFLAMMASOME
ACTIVATION AND PRESERVES FUNCTIONAL RECOVERY AFTER
INTRACEREBRAL HEMORRHAGE IN MICE2
Introduction
While intracerebral hemorrhage (ICH) accounts for only 10-15% of all strokes,
mortality rates after ICH can reach >50%, and approximately 74% of those who do
survive experience severe disabilities and post-stroke cognitive impairment (van Asch et
al., 2010). Unfortunately, surgical intervention is the only option, as there are no effective
therapeutic treatments for ICH (Broderick et al., 2007; de Oliveira Manoel, 2020). The
resulting hematoma within brain parenchyma induces a series of adverse events, causing
primary and secondary brain injury. Primary brain damage includes edema, which
induces mass effects and increased intracranial pressure that can lead to herniation and
death. Secondary brain damage results from activation of microglia, which drives proinflammatory cytokines as well as oxidative and cytotoxic cascades that lead to cell death
and functional impairment (Shao et al., 2019). These inflammatory and oxidative factors
also stimulate expression of matrix metalloproteinases, a gene family of extracellular
matrix enzymes, which degrades junction proteins like zonula occludens-1 (ZO-1) and
increases the blood-brain barrier (BBB) permeability after stroke (van Asch et al., 2010)
and ICH (Keep et al., 2008) to create further damage and worsen prognosis. Hence, there
is an urgent need to better understand the pathways/targets that are active after ICH to
develop effective therapies.
Although the precise mechanisms underlying secondary brain injury after ICH are
complex and poorly understood, several studies have suggested that inflammatory
responses are likely to be a prominent early feature in the pathogenesis of ICH (Broderick
et al., 2007; Shao, Tu, and Shao, 2019). Microglial cells play critical roles in the
pathophysiology of ICH by regulating inflammation, innate immune response, and
hematoma resolution, the key determinants of secondary brain damage and functional
recovery after ICH (Broderick et al., 2007). Thioredoxin-interacting protein (TXNIP) is a
binding partner of thioredoxin (TRX) and functions as a negative regulator of the TRX
reductase activity (Nasoohi et al., 2018). TXNIP is an intriguing candidate molecule that
links glucose/oxidative stress and inflammation to cellular injury, making it a multifaceted
target for neurovascular degeneration (Ishrat et al., 2015;Mohamed et al., 2015; Nasoohi,
Ismael, and Ishrat, 2018; Nasoohi, Parveen, and Ishrat, 2018). Recently, we and others
demonstrated that ischemic stroke-induced TXNIP upregulation is associated with
increased brain damage and a higher incidence of hemorrhagic transformation (HT) in
hyperglycemic conditions, an important comorbidity associated with increased risk of
hemorrhage and poor stroke recovery (Capes et al., 2001; Hafez et al., 2014; Ismael et al,
2020). TXNIP also participates in early brain injury after subarachnoid hemorrhage
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(SAH) by mediating inflammation (Tsubaki et al., 2020; Zhao et al., 2017). Moreover,
TXNIP is required for activation of the NOD‐like receptor protein 3 (NLRP3)inflammasome, a multi-protein complex involved in instigating inflammation and
immune regulation in several neurovascular injury models including ICH (El-Azab et al.,
2014; Ishrat et al., 2015; Mohamed et al., 2014; Mohamed et al., 2015; Nasoohi et al.,
2018). The NLRP3 inflammasome is composed of oligomers of the pattern recognition
receptor NLRP3, apoptosis-associated speck-like (ASC) adapter protein, and the
downstream effector enzyme pro-caspase-1. Following NLRP3-inflammasome
activation, NLRP3 responds by recruiting and assembling with the ASC, which in turn
recruits pro-caspase-1, causing its cleavage and activation into active cleaved caspase-1
(Cl-Cas-1). Activated cleaved caspase-1 then cleaves pro-IL-1β into the active cleaved
IL-1β (Cl-Cas-1) form, which exerts its well-founded detrimental pro-inflammatory and
pro-apoptotic effects upon release into the extracellular environment (Martinon et al.,
2002). Moreover, NLRP3 activation is mainly located in microglia (Yang et al., 2014; Ye
et al., 2017), which are among the first non-neuronal cells on the scene during the innate
immune response to ICH. Together, these findings suggest that TXNIP is a promising
new therapeutic target, serving as an upstream molecular link between inflammation and
neurovascular damage.
Although TXNIP lacks a specific pharmacological inhibitor, we and others have
demonstrated that verapamil is an effective inhibitor of TXNIP in vivo (Al-Gayyar et al.,
2011; Chen et al., 2009). Verapamil is a commonly prescribed phenylalkylamine L-type
calcium (Ca2+) channel blocker (CCB) with nonspecific TXNIP inhibitor properties and
has been approved by the FDA for treatment of angina, hypertension, and arrhythmias
(Popović et al., 2020). It is also used as the first line in the prevention of cluster
headaches (Petersen et al., 2019). Pharmacological studies have shown that verapamil has
a wide therapeutic spectrum, including antihypertensive, anti-inflammatory, and
antioxidative effects and regulation of the BBB function, due to its effect on Pglycoprotein as well as adjustment of cellular Ca2+ homeostasis (Ismael et al., 2021a;
Ismael et al., 2021b; van Assema et al., 2012). Recent studies from our group and others
have indicated a potential positive effect of verapamil in neurological disorders, including
cognitive deficits and ischemic stroke (Ismael et al., 2021a; Ismael et al, 2021b; Jackson
et al., 2018; Melone et al., 2018; Popović et al., 2020).
Our recent study supports the use of verapamil as a safe adjunct therapy in
thrombolytic approaches for neurovascular complications (such as HT) associated with
hyperglycemic conditions after ischemic stroke (Ismael et al., 2021). It reasons that
similar benefits may be observed during the administration for ICH. Therefore, this study
will be the first to determine whether verapamil affects the TXNIP-NLRP3 axis’
contribution to neuroinflammation and long-term functional recovery after ICH, which
will lead to the development of new therapeutic strategies for hemorrhagic stroke.
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Methods and Materials
Experimental Procedure and Treatment Regimen
All animal experiments conformed to standard procedures approved by the
Institutional Animal Care and Use Committee (IACUC) at UTHSC. The studies were
reported in accordance with ARRIVE (Animal Research: Reporting in Vivo
Experiments) guidelines (Kilkenny et al., 2010). Adult (10–12 weeks old) male C57Bl/6
mice (Jackson Laboratory, Bar Harbor, ME, USA) were housed in standard conditions of
humidity (45–50%), temperature (21–25 °C), and a 12-h light/dark cycle with ad lib
access to food and water. Animals were assigned to three experimental groups: 1) Sham
+ saline, 2) ICH + saline, and 3) ICH + verapamil, n=5-9/group. Verapamil (Sigma,
USA) was dissolved in sterile saline and acutely administered (0.15 mg/kg,
intravenously) 1 h post-ICH followed by oral administration (1mg/kg/day) in drinking
water. The verapamil dose was determined based on previous publications (Fraser et al.,
2017; Maniskas et al, 2016). The animals were evaluated for two endpoints: (1) 72 hours,
to study the acute effect of TXNIP modulation in ICH (n=7/group); and (2) 30 days, to
evaluate long-term functional outcome (n= 5-8/group). The experimental design is
depicted in Figure 4-1.
Induction of ICH in Mice
ICH was induced in adult male C57BL/6 mice, as reported previously (Ahmed et
al., 2018). Briefly, experimental animals were anesthetized using 3% isoflurane and
maintained with 1.5–2% during surgery. Animals were then placed on a stereotaxic head
frame, and a burr hole (0.5 mm) was made on the skull 2.2 mm lateral to bregma.
Intrastriatal injection of bacterial type IV collagenase (0.045 U in 1 μL PBS, Sigma, St.
Louis, MO) was completed with stereotaxic guidance for 3.0 mm into the right striatum
by using a 26-G Hamilton Syringe. The temperature was monitored and maintained at
37±2°C during surgery using a homeothermic heating blanket (Kent Scientific). The
animals were allowed to recover from anesthesia on the heating pad and then returned to
their home cages. Sham-operated animals were subjected to a similar surgery procedure
without collagenase injection.
Rotarod
Motor impairment was evaluated using an accelerating rotarod (Med Associates,
Inc., VT, USA). Rotarod tests were performed according to our previous studies (Ishrat et
al., 2009). All animals were given 3 training sessions 10 minutes apart before surgery to
establish baseline performance. Animals were first habituated to the stationary rod and
then exposed to the rotating rod at basal speed. The rod was started at 3 revolutions per
minute (rpm) and accelerated linearly to 30 rpm within 300 seconds. Latency to fall off
the rotarod was then determined before ICH (pre-surgery) and at 72 hours post-ICH. To
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Figure 4-1.

Schematic representation of experimental design.
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complete testing, animals were required to stay on the accelerating rod for a minimum of
30 seconds. If they were unable to reach this criterion, the trial was repeated a maximum
of three times. The two best (largest) fall latency values an animal could achieve were
then averaged and used for data analysis. Animals not falling off within 5 min were given
a maximum score of 300 seconds.
CatWalk Test
The Catwalk test was performed to assess gait control parameters in animals
following ICH, which is intimately affected by sensorimotor frailty (Herbin et al., 2007).
The Catwalk XT is an advanced video-based gait analysis system that dynamically
measures the footprints of voluntarily moving animals. The system records animals’
footprint images, and foot force profiles are captured by a camera mounted underneath a
glass walkway (Ismael et al., 2018). These initial recordings work as inputs into the
CatWalk XT software package (Noldus Information Technology, Wageningen, The
Netherlands) to calculate the specified indices.
Basic measures of gait cycles were obtained by the Catwalk system to
automatically calculate several variables including “Gait/Step cycle,” “Paw intensity,”
and “Inter-paw coordination,” each detailed in the supplementary materials. Step cycle
indicates the time needed to complete a single cycle of a step, with the duty cycle being
the percentage of the whole step cycle covered by the stance phase. Duty cycle is
described by percentage of the step cycle. Paw intensity reflects the maximal weight over
the paws and mirrors any gait shift during the gait cycle. Finally, “Inter-paw
coordination,” mostly addressed by phase dispersion, reflects gait shift derangement,
galloping, or limping by comparing anchor paws’ step cycles.
Novel Object Recognition (NOR) Test
Based on the spontaneous tendency of rodents to explore and interact with a new
object, the novel object recognition test (NOR) was utilized to evaluate animals’ nonspatial, short-term working memory (Ishrat et al., 2006). Through a standard test
procedure, animals were allowed to explore two identical objects (acquisition trial), one
of which was replaced in the next phase (preference trial). In the habituation phase (10
minutes) conducted 1 day before the start of the test, animals were allowed to acclimate
to an empty standard-sized box (45x45x35cm). On the designated test day, animals were
first presented with 2 identical objects and for 5 minutes were allowed to explore the
objects that were placed equidistant from the walls of the box, in the center, and spaced
20 cm apart (acquisition trial).
Following sample object exposure, the animals were returned to their home cage
for a 90minute retention period. The 2nd preference/test trial (5 minutes) was conducted in
the same manner as the first trial except that a new/novel object replaced one of the
familiar/sample objects (preference trial). The interval between sample and test trials was
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adjusted to 5 minutes for selective testing of short-term working memory. The time
animals spent exploring familiar and new objects were recorded to calculate recognition
index (RI) as indicators of working memory using the following formula (Equation 4-1):
Recognition index (RI) = TN / (TN + TF)

(Eq. 4-1)

where TF and TN are the times spent interacting with the familiar and novel object,
respectively.
Morris Water Maze (MWM) Test
The Morris water maze (MWM) was used to assess animals’ spatial learning and
memory through a combination of training and probe trials (Ahmed et al., 2018). The
initial learning/training phase consisted of 28 total trials. These were conducted as single
daily sessions of 4 trials, 60 seconds each, and a trial interval of approximately
30 seconds for 7 consecutive days. In brief, training trial animals were allowed to learn
the location of the hidden escape platform submerged 2 cm below the surface of the
water (25 ± 2 °C) in a circular water tank (132 cm diameter and 60 cm height) divided
into 4 virtual quadrants. On each trial day, animals were allowed to swim freely on four
trials (once from each starting position). If the animal failed to reach the escape platform
within the maximal allowed time of 60 seconds, it was gently placed on the platform and
allowed to remain there for 30 seconds. Fixed flags on particular quadrants were used as
spatial cues for the animals. The time to reach the hidden platform underneath the water
(escape latency) was recorded as the index of learning. Spatial reference memory and
memory consolidation were assessed with a standard place task/probe test conducted 24
hours (on day 8) after the last daily training session. During the probe test, the platform
was removed and animals allowed to swim freely in the pool for 60 seconds. The time
spent and distance moved in the target quadrant indicated the degree of memory
consolidation that had taken place 24 hours after learning.
Determination of Hematoma Volume
The whole brain of each mouse (n =4/group) was sliced into 1 mm serial coronal
sections with the help of brain matrix. Hematoma volume was determined using Image J
software (NIH, USA) wherein the area of the hematoma was quantified.
Western Blot Analysis
After sacrifice at 72 hours post-ICH induction, whole brains were rapidly
dissected into 4.0 mm coronal sections (≈ 0.5 and −3.5 mm from bregma) using a matrix.
Perihematomal regions were extracted for Western blot analysis, as previously described
(Ismael et al., 2018). Briefly, brain tissues were homogenized with a RIPA buffer
containing protease and phosphatase inhibitor cocktails. Protein concentrations were
determined using the BCA Method (Thermo Scientific USA.). A total of 30 µg protein
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was loaded into each lane and resolved, followed by transfer to PVDF membranes. The
membranes were blocked for non-specific binding with 5% skimmed milk and probed
with primary antibodies against NLRP3, caspase-1, ASC (1:1000; AG-20B-0014; AG20B-0042; AG-25B-0006; Adipogen Life Sciences), TXNIP (1:1000; NBP1-54578SS;
Novus Biologicals), ZO-1 (1:1000; SC7273; Cruz Biotechnology), cleaved IL-1β,
Phospho-NFκBp65 (ser536), NFκBp65, TRX, GLUT1(1:1000; 11948; 3033; 3034; 2429;
12939; Cell Signaling Technology), and β-Actin antibody (1:10,000; A5316 Sigma) at
4oC overnight. Following TBS-T washes, the membranes were incubated with
horseradish peroxidase (HRP)-conjugated, anti-mouse IgG antibody and an anti-rabbit
antibody (1∶10000; A9044; A9169; Sigma USA) for 1 hour at room temperature. The
bands were then visualized using an enhanced chemiluminescent substrate system
(Thermo Fisher Scientific) and analyzed by densitometry using Image-J 1.51J8 software.
These were normalized to loading controls and expressed as fold change.
Slot Blot Analysis
Nitrotyrosine (NT) immunoreactivity was measured by slot blot analysis. In brief,
brain tissue homogenate was prepared in a lysis buffer, and 25 μg protein were
immobilized onto a nitrocellulose membrane from each group using a slot blot microfiltration unit. After blocking with 5 % non-fat milk, the membrane was incubated against
an anti-nitro tyrosine antibody and visualized by enhanced chemiluminescent substrate
system (Thermo Fisher Scientific). The optical density was quantified using ImageJ
software.
Immunoglobulin Extravasation
Extravasation of endogenous Immunoglobulin G (IgG) was performed to assess
BBB permeability following stroke. Penumbral proteins (30 μg/well) were sizefractionated on SDS-Page gels and electroblotted on a PVDF membrane. Blots were then
incubated with horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody
(1∶10000; A9044; Sigma USA) for 1 hour at room temperature and processed for
visualizing the immunoreactive signal. The protein bands were quantified using Image J
software.
Immunofluorescence Staining
At 72 hours after ICH, mice were anesthetized with ketamine/xylazine and
transcardially perfused with ice cold PBS (30 ml). Brains were then removed and postfixed in 10% buffered formalin overnight at 4 °C and then sequentially immersed in 30%
sucrose in PBS solution for 72 hours. The brains were sectioned in the coronal plane at a
thickness of 10 microns and blocked with Serum-Free Protein Block (X0909, DAKO)
followed by incubation with primary antibodies against TXNIP (1:100; NBP1-54578SS;
Novus biologicals) at 4°C, overnight in a humid chamber. Sections were washed and
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incubated with fluorescent anti-mouse secondary antibodies (1:200; 072-04-18-03;
Dylight-549, KPL) for 1 h at room temperature. For double staining, the process was
repeated with primary antibodies against Neu-N (1:250; ABN78, Millipore), Iba-1
(1:250; WDF6884; WAKO) or GFAP (1:500; 20334, Dako). After single or doublestaining, sections were mounted with ProLong™ Diamond Antifade Mountant with
DAPI (Invitrogen) and viewed using a Zeiss 710 confocal laser-scanning microscope.
Negative controls were prepared by omitting the primary antibodies.
Statistical Analysis
All results were expressed as mean ±SE and calculations were obtained using
GraphPad Prism software. Studen’'s t-test or one- or two-way ANOVA was performed
followed by Tuke’'s test for individual comparisons. The criterion for statistical
significance was set at p<0.05.
Results
Verapamil Treatment Reduced Hematoma Volume, Oxidative Stress, and Inhibited
ICH-Induced TXNIP-NLRP3 Inflammasome Activation
To determine the molecular changes associated with TXNIP modulation with
verapamil treatment, an acute (72 hours) study was performed (Figure 4-2). ICH was
induced as previously described, and animals were treated with verapamil. Hematoma
volume was calculated from serial coronal sections. The data showed qualitatively that
verapamil reduced the hematoma volume in ICH animals, although this result did not
achieve statistical significance (Figure 4-2A). Further, TXNIP and components of
NLRP3 expression were analyzed by Western blot in the perihematomal area at 72 hours
after ICH (Figure 4-2B, 4-2F-H). The expression of TXNIP was significantly (p=0.017)
increased in the ICH group compared to shams along with reciprocal down-regulation of
antioxidant thioredoxin TRX (p=0.001) (Figure 4-2B, C), suggesting that ICH induces
the activation of TXNIP. Interestingly, verapamil administration significantly (p=0.049)
inhibited the expression of TXNIP compared to the ICH-vehicle group (Figure 4-2B).
Cell-specific expression of TXNIP was further examined either in ICH cortical sections
by immunohistochemistry. Slot blot analysis has shown that ICH induced oxidative
stress, which is evident by increased nitrotyrosine (NT) level (Figure 4-2D), an indicator
of super oxide-dependent peroxynitrite formation (Ismael et al., 2021). Treatment with
verapamil significantly attenuated NT levels. Our result showed that TXNIP is
colocalized with NeuN, GFAP, and Iba-1, suggesting that TXNIP overexpressed in
neurons and glial cells such as astrocytes and microglia (Figure 4-2E). Further, we
examined the effect of TXNIP inhibition on the expression of TRX. However, verapamil
did not modulate the TRX expression in ICH animals (Figure 4-2C).
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Figure 4-2. Administration of verapamil-ameliorated hematoma volume and
TXNIP-associated NLRP3 inflammasome activation in mice after ICH.
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One of the consequences of TXNIP activation is the direct activation of the
NLRP3 inflammasome (Ismael et al., 2021a; Ismael et al, 2021b). The principal
constituents of NLRP3 inflammasome assembly, as well as the consequent caspase-1 and
IL-1β synthesis, were analyzed to determine the inflammasome activation in
perihematomal regions. Our results showed that the expression of NLRP3 inflammasome
products, such as cleaved caspase-1 (p=0.05) and cleaved IL-1β, were significantly
(p=0.0001) elevated at 72 hours after ICH when compared to shams, although NLRP3
itself did not show significant elevation (Figure 4-2F-H). Further, treatment with
verapamil inhibited ICH-induced NLRP3 inflammasome activation, as evidenced by
reduced expression of cleaved caspase-1 (p=0.06) and cleaved IL-1β (p=0.001); however,
verapamil administration did not provide a discernible effect on NLRP3 protein level
(Figure 4-2F-H). The contribution of NLRP3 inflammasome activation following stroke
is established in earlier studies to contribute to stroke injury through the proinflammatory cytokines as well as the pleiotropic effects of cleaved caspase-1 in
mediating pyroptosis and apoptosis (Melone et al., 2018).
Verapamil Treatment Attenuated Inflammatory Priming and Pro-Inflammatory
Microglial Markers After ICH
We further elucidated the effect of verapamil on phosphor- NFκBp65/NFκBp65
as an index for activation of NFκB, the transcriptional regulator of inflammatory genes in
the perihematomal area at 72 hours after ICH (Figure 4-3A). There was higher
expression (p=0.08) of45etabolio-NFκBp65/NFκBp65 in the ICH-vehicle group as
compared to shams, which was marginally inhibited by verapamil treatment. To examine
the effect of verapamil on microglial activation, we next determined the expression of the
pro-inflammatory microglial markers Iba-1 and EZH2 at 72 hours after ICH (Figure
4-3B, C). The expression of Iba-1 and enhancer of zeste homolog-2 (EZH2) were
increased after ICH compared to shams. EZH2 histone methyltransferase plays a critical
role in microglial activation (Chen et al., 2019).
Treatment with verapamil significantly (p=0.03) reduced expression of these proinflammatory microglial markers in the ICH-verapamil group compared to the ICHvehicle group (Figure 4-3B, C). Consistently, immunohistochemical analysis
demonstrated elevated immunoreactivity to Iba-1, which is ameliorated by treatment with
verapamil (Figure 4-3D, E).
Verapamil Alleviated Blood Brain Barrier Permeability After ICH
BBB disruption is a key pathophysiological feature of ICH. ZO-1 level has been
closely associated with the degree of BBB damage and has been established as an
indicator of BBB destruction. Next, we examined the effects of verapamil on the level of
BBB junction protein ZO-1 at 72 hours after ICH (Figure 4-4A). The level of ZO-1 was
significantly (p=0.01) decreased in the ICH-vehicle group compared to shams.
Administration of verapamil marginally attenuated ZO-1 expression in ICH-verapamil
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Figure 4-3. Inhibition of TXNIP with administration of verapamil ameliorated
NFkB activation and microglial activation in mice after ICH.

Figure 4-4. Administration of verapamil-attenuated, ICH-induced BBB
breakdown in mice after ICH.
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compared to the ICH-vehicle group (Figure 4-4A). Also, we examined the effect of
verapamil on IgG extravasation, a marker of BBB disruption after ICH, by using the
immunoblotting of endogenous IgG heavy and light chains at 72 hours after ICH. In the
final analysis, we found a significant increase in expression of IgG heavy chain (p=0.008)
and light chain (p=0.008) in the perihematomal regions of the brain (Figure 4-4B, C).
Verapamil significantly (p=0.014) attenuated the brain level of IgG light and heavy chain.
Effect of Verapamil Treatment on Rotarod Performance After ICH in Mice
Rotarod performance is expressed as a percentage of pre-surgery control value.
The rotarod tests showed significant (p<0.05) deficits in motor performance (time spent
on the rotarod) in the ICH-vehicle group at 72 hours post-ICH compared to shams.
Treatment with verapamil showed a trend (p=0.06) toward improved rotarod performance
in the ICH-verapamil group compared to the ICH-vehicle group (Figure 4-5A).
Verapamil Administration Improved Gait Control Indices Post-ICH in Mice
The CatWalk measured several different gait indices across all limbs and the
body. Those mice treated with verapamil demonstrated improvements across many of
these indices when compared with saline groups. The ICH-vehicle groups showed a
significant increase in body speed variation (p=0.047) and run variation (p=0.0301) when
compared to the sham group. Interestingly, treatment with verapamil showed no
significant improvement from the vehicle group. Paw intensity for both the left hind
(p=0.049) and right hind (p=0.042) paws showed a significant increase in the ICHvehicle group compared to the sham group. The verapamil treatment significantly
(p=0.033) decreased these intensities like that observed in the sham group. The inter-paw
coordination was measured by paw coupling the mean coupling of the left forepaw with
the left hind paw and showed a significant (p=0.05) decrease in the ICH-vehicle group
when compared to the sham group. However, the ICH-verapamil group showed a
significant (p=0.02) increase in the coupling, when compared to the vehicle group, that
was on par with the sham. The reverse was shown when looking at the pairing of the left
forepaw with the left forepaw. The ICH-vehicle group showed a significant (p=0.05)
increase in the vehicle group when compared to the sham. The verapamil group showed a
significant (p=0.043) decrease in mean couplings when compared to the ICH-vehicle
group. The single stance phase of the right hind paw showed a significant (p=0.031)
mean decrease in the level ICH-vehicle group compared to the sham. The ICH-verapamil
group showed a significant (p=0.029) increase in the single stance phase when compared
to the vehicle group, further demonstrating the effect verapamil has in improving
coordination. Lastly, the mean duty cycle of the left hindlimb showed a significant
(p=0.05) decrease in the ICH-vehicle group when compared to the sham group. The
verapamil group showed a strong decreasing trend (p=0.08) toward significance when
compared to the ICH-vehicle group (Figure 4-5B, C).
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Figure 4-5. Rotarod and CatWalk XT system was used to evaluate the motor and
gait control indices.
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Verapamil Improved Non-spatial Working Memory Post-ICH in Mice
Novel object recognition was used to assess short-term recognition memory of the mice
following ICH (Ishrat et al., 2006). A Recognition index (RI) was calculated for each
mouse in each group, and the average score was compared amongst groups. The RI was
calculated from the ratio of time spent on a novel object to total exploration time. A
significant (p=0.019) decrease in recognition index was observed in ICH-mice at 21 days
post-ICH compared to sham animals (Figure 4-6A, B). Interestingly, verapamil treatment
improved preference towards the novel object in ICH mice, represented by improved
recognition indices. However, the improvement was not statistically significant.
Long-Term Verapamil Treatment Improved Spatial Reference Memory Post-ICH
The Morris water maze (MWM) was used to determine the spatial learning and
spatial memory of the mice following ICH, as previously described (Ahmed et al., 2018).
Escape latency was calculated for 7 days of hidden platform as an average of four trials
per day and considered as the measure of spatial learning. Over the seven days of hidden
platform training, there was an increased mean escape latency in ICH animals (regardless
of verapamil administration) when compared to sham animals (Figure 4-6C); this
difference was significant for day 6 (p=0.0051) and day 7 (p=0.0064), showing that ICH
impaired spatial learning. However, we did not find a significant difference in spatial
learning between the ICH-verapamil group and the ICH-vehicle group over the seven
days of hidden platform training, indicating that verapamil did not improve spatial
learning in ICH animals (Figure 4-6C).
A probe trial was performed to evaluate reference memory consolidation in ICH
animals after 24 hours of hidden platform training. The ICH-vehicle animals failed to
remember the location of the platform and spent significantly less time (p=0.042) in the
target quadrant than sham animals (Figure 4-6D). Verapamil treatment improved the
spatial reference memory indicated by a strong trend (p=0.06) toward the retention of
spatial memory with an increase in time spent in the target quadrant compared to ICH
mice that were not given verapamil (Figure 4-6D). Additionally, the average number of
times the mouse entered the target quadrant, the average distance (m) traveled in the
target quadrant, and the average speed (m/s2) in the target quadrant was also used to test
different aspects of spatial memory. The ICH-vehicle group showed a significant
decrease (p=0.049) in the average distance traveled in the target quadrant and a decrease
in the average number (frequency) of target quadrant entries (p=0.0155) when compared
to the sham group (Figure 4-6E, D). The ICH-verapamil group showed significant
retention of spatial memory, illustrated by an incremental trend in the number of target
quadrant entries (frequency) and a significant decrease (p=0.05) in the average distance
traveled in the target quadrant. There was no significant difference in the average speed
of mice between any of the three groups (Figure 4-6H).
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Figure 4-6. Effect of long-term TXNIP inhibition with verapamil on cognitive
decline in ICH animals.
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Discussion
Here, we report for the first time that inhibition of TXNIP with the administration
of verapamil improved neuroinflammation, BBB damage, and acute neurological
outcome after ICH, implicating the contributory role in TXNIP in the pathophysiology of
ICH. Through treatment, we were able to illustrate a decrease in cellular damage in the
form of bleeding and hematoma size similar to treatments utilized in previous studies
(Bonsack & Sukumari-Ramesh, 2021; Hanley, 2009; King et al., 2011; Wagner et al.,
2003). Verapamil has demonstrated its potential in a multitude of neurovascular (Jangholi
et al., 2020; Popović et al., 2020), neurodegenerative, and cognitive conditions (Ismael et
al., 2021; Kumar et al, 2016; Melone et al., 2018; Popović et al., 1997). Furthermore, our
most recent studies have demonstrated that verapamil inhibits TXNIP in order to protect
against brain damage in hyperglycemia-associated ischemic stroke and sporadic AD
mouse models (Ahmed et al., 2021; Ismael et al., 2021). As a result of this, our findings
support that verapamil inhibits TXNIP as well as improves outcome in a murine model of
ICH. However, verapamil did not affect the expression of TRX after ICH.
Although the pathophysiologic mechanisms of secondary brain injury are not
fully understood, several recent studies have reinforced the observation that
neuroinflammation plays a critical role in the secondary brain damage after ICH
(Aronowski & Zhao, 2011; Wang & Doré, 2007). The inflammatory pathways are rapidly
activated in response to the presence of blood components in the tissue and are
characterized by activation of inflammatory cells such as microglia and astrocytes and
secretion of inflammatory cytokines (Shao et al., 2019; Tschoe et al., 2020).
The damaged and dead neuronal cells51etaboate the release and synthesis of
damage-associated molecular patterns (DAMPs), which further increases microglial
activation and proinflammatory responses (Zhou et al., 2014). Here, the verapamilmediated improvement in neurological outcome after ICH was associated with an
inhibition in neuroinflammatory responses. Our immunoblotting analysis showed
elevated TXNIP expression is associated with increased activation of NLRP3
inflammasome components, such as cleaved caspase-1 and IL-1 β. Importantly, TXNIP is
required for NLRP3 inflammasome activation, a recently discovered mechanism
mediating inflammatory response in several diseases including ICH (El-Azab et al., 2014;
Ishrat et al., 2015; Mohamed et al., 2014; Mohamed et al., 2015). Furthermore, genetic
deletion or pharmacological inhibition of NLRP3 signaling rescued brain damage after
ICH (Chen et al., 2021; Ren et al., 2018). In our study, verapamil treatment significantly
attenuated NLPR3 activation by inhibiting cleaved caspase-1 and IL-1β despite no
change in NLRP3 itself. This is consistent with the anti-inflammatory potential of
verapamil (Ismael et al., 2021), implicating that attenuation of inflammasome activation
could partly be responsible for verapamil-mediated neuroprotective effects after ICH. In
addition, verapamil also marginally decreased the hematoma volume, clinically a major
determinant of adverse outcome following ICH (LoPresti et al., 2014).
In addition to NLRP3 inflammasome activation, ICH induced upregulation of NFkB. NF-kB is critical regulator of neuroinflammation following ICH, which mediates the
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priming of proinflammatory cytokines such as TNF-α and IL-1β (Wagner, 2007).
Inhibition of TXNIP with verapamil marginally attenuated elevated activation of NF-kB
after ICH. When the NF-kB pathway is pharmacologically inhibited, there has been a
demonstrated attenuation of ICH brain injury in rats (Song et al., 2020). This attenuation
of injury is consistent with what we found in our experiment.
Our results here also demonstrated that ICH induced expression of EZH2, a
histone-lysine N-methyltransferase involved in microglial activation and
neuroinflammation through NFkB-mediated mechanism (Luo et al., 2020), was reduced
by administration of verapamil. This observation is consistent with previous reports that
inhibition of EZH2 attenuated microglial activation and the secretion of proinflammatory
cytokines after ischemic stroke and SAH (Chen et al., 2019; Luo et al., 2020). Microglia
are the first non-neuronal cells activated in response to ICH and aggravate ICHassociated brain injury by secreting various chemokines and cytokines (Aronowski &
Hall, 2005). Furthermore, ICH elevated Iba-1 positive microglia with dense cytoplasm
and dense processes in the perihematomal region, which was also attenuated by
verapamil administration.
One of the consequences of inflammatory responses following ICH is elevated
BBB disruption and permeability (Wang & Doré, 2007), which significantly contributes
to the development of secondary brain injury and subsequent mortality and neurological
impairment (de Oliveira Manoel & Macdonald, 2018). A loss of BBB integrity
aggravates the inflammatory response by leukocyte influx and brain edema formation
(Keep et al., 2008). In addition to elevated neuroinflammation, our ICH animal model
showed significantly elevated extravasation of immunoglobulin G light chain and heavy
chain and down-regulation of ZO-1 junctional protein, demonstrating increased BBB
permeability. Verapamil administration not only significantly attenuated extravasation of
immunoglobulins; it also revealed a strong trend toward the modulation of ZO-1. We
have previously reported the potential benefit of verapamil in attenuating BBB
permeability in a mouse model of ischemic stroke through inhibition of TXNIP (Ismael et
al., 2021).
Neurobehavioral analysis highlighted many important revelations concerning ICH
and verapamil’s role in the treatment of ICH. We found a significant motor deficit in our
animal model at 72 hours following ICH, evidenced by lower rotarod performance and
sensory-motor abnormalities, illustrating the model has applicability for the clinical
scenario. In our animal model, ICH affects gross motor function at 72 hours after injury
and that ICH has long-term cognitive effects. The strong trend toward improved rotarod
performance in the ICH-treatment group suggests there may be a reduction of motor
function deficits when verapamil treatment is given after hemorrhage. The CatWalk
analysis showed verapamil is effective in improving the gait control indices (e.g., duty
cycle and intensity of hind limb use) and inter-paw coordination following stroke. While
these findings seem promising, many translational hurdles between humans and animal
models still need to be addressed before this treatment can be applied to stroke patients.
In this present study, ICH induced significant impairment in cognitive function, with
decreased performance seen in NOR and MWM. The recognition index was used as the

52

measure of non-spatial working memory, and MWM was used to evaluate the spatial
learning and reference memory. Long-term verapamil administration has beneficial
effects on cognitive function, including non-spatial working memory and spatial
reference memory despite no change in spatial learning. This is consistent with our
previous report that verapamil attenuated age-associated senile dementia and cognitive
impairment in sporadic AD (Ahmed et al., 2021; Ismael et al., 2021; Popović et al.,
1997).
Given the efficacy of verapamil in improving neurological outcomes after ischemic
stroke and AD (Ahmed et al., 2021; Ismael et al., 2021), this study was designed as a proofof-concept study to test the potential of verapamil in attenuating neurological outcome ICH
outcomes. Our findings demonstrated that low doses of verapamil attenuated brain injury,
neuroinflammation, and blood BBB dysfunction in a murine model of ICH. Further longterm treatment with verapamil improved motor function and cognitive impairment through
inhibition of TXNIP. Our findings show the possible therapeutic effects of verapamil
treatment for ICH and the biological pathways influenced by this treatment. Future studies
should be done to focus on identifying most efficacious dose of verapamil for long-term
neuroprotection and improvement of neurological outcomes after ICH in an age- and sexindependent manner. Future studies are also necessary to further elucidate the contributions
of TXNIP in ICH outcomes, particularly through experiments using more potent, specific
inhibitors such as TXNIP-IN- (Liu et al., 2021) and SRI-37330 (Thielen et al., 2020).
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CHAPTER 5.

CONCLUSION

Summary
The aim of this dissertation research was to better characterize the inflammatory
environment following hemorrhagic stroke. To achieve this, we focused on two different
forms of hemorrhagic stroke: aneurysmal subarachnoid hemorrhage (aSAH) and
intracerebral hemorrhage (ICH), and investigated the role of several inflammatory
molecules, including various cytokines, NLRP3, and TXNIP, in severity and recovery
trajectories. We also included relevant clinical and behavioral data for these inquiries and
utilized both patient samples and animal models to address the translational implications
of our research questions.
This project was broken up into three portions. In Chapter 2, we conducted a
literature review to better understand the scope of the research that has taken place
regarding inflammatory cytokines involved in SAH. We aimed to identify the gaps
present in the research and the nature of the research being done in both animal models
and in human patients. We found that three main pro-inflammatory cytokines (IL-1β, IL6, and TNF-α) demonstrate reliable increases following aSAH across the included
studies. While this is a promising area of research for potential therapeutics, there are
gaps in the knowledge base that remain and which bar progress for clinical translation of
this information from animal models to human patients. In particular, there is a need for
investigations that explore the systemic inflammatory response following injury in a
more diverse number of cytokines, the balance of specific pro-/anti-inflammatory
cytokines, and how these biomarkers relate to patient outcomes and recovery over time.
In Chapter 3, we aimed to fill one of these gaps by comparing the inflammatory
cytokine environment across rat and human subjects and in CSF and plasma samples
following aSAH. We found that in both humans and rats, the absolute cytokine levels of
IL-6 and IL-8 were significantly higher than all other cytokines. In humans, the localized
cerebral environment demonstrated a greater cytokine-mediated inflammatory response,
though this difference was not observed in the rodents. Several cytokines were associated
with age, sex, diabetes, smoking, and Fisher score; IL-6 and IL-8 again demonstrated the
most robust associations (p<0.05). With further clinical correlation in individual patients,
it is possible that these changes could possibly serve as targets for improved treatment
options following aSAH.
Lastly, in Chapter 4 we utilized a mouse model of ICH to better characterize the
inflammasome and other major proteins that are involved in inflammatory response poststroke. The antihypertensive drug verapamil was administered to ascertain its capabilities
in managing the inflammatory response following ICH and how this intervention impacts
behavioral recovery. We found that verapamil treatment reduced expression of TXNIP
and NOD-like receptor pyrin domain-containing-3 inflammasome activation in the
perihematomal area. These protective effects were associated with decreased
proinflammatory mediators, microglial activation, and blood-brain barrier (BBB)
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permeability markers. Our findings also demonstrated that long-term, low-dose verapamil
effectively attenuated motor and cognitive impairments. Taken together, these data
indicate that verapamil has therapeutic potential in improving acute motor function after
ICH. Further investigations are needed to confirm whether verapamil treatment could be
a promising candidate for future clinical trials.
Implications for Hemorrhagic Stroke
When these results are taken together, this research answers some interesting
questions regarding the inflammatory response following hemorrhagic stroke. Much of
the research conducted to date only investigates specific cytokine change at a single
timepoint in relationship to recovery or severity of stroke. While this is appropriate in
initial inquiry, the multifaceted effects of stroke indicate that there are likely many
complex inflammatory checks and balances. An expansion of research into uncovering
the entire cytokine constellation, and into the change of individual trajectories over time,
should be considered in future work.
Next, our research was able to show that the animal models we have are grossly
representative of the human condition is some ways while being different in others. We
confirmed that IL-6 and IL-8 (KC/GRO in rats) are the principal cytokines released
following aSAH. However, we also demonstrated that that the local inflammatory
response in CSF is much more robust in humans as compared to rats. There may be
several factors such as genetic differences, leukocyte distribution differences, and clinical
treatment protocols in humans that may be responsible for these differences. Further
investigations into understanding these similarities and differences will serve to validate
what has been done so far and also better inform translational implications of work
conducted in animal models for future therapeutics.
The work here also better illustrated the role of NLRP3 and TXNIP following
ICH and the effect of verapamil treatment. Following ICH, we observed elevated TXNIP
and NLRP3 products such as cleaved caspase-1 and cleaved IL-1β, results that indicate
that the TXNIP-NLRP3 inflammasome is responsible for the primary cytokine response
following hemorrhagic stroke. Following treatment with verapamil, we were able to
observe a decrease in these products and TXNIP, an observation that was similar to the
levels seen in the sham group. Similar improvements were also observed in memory and
motor metrics following verapamil administration, indicating that verapamil could serve
as a possible therapeutic following hemorrhagic stroke.
Limitations
There were some limitations we encountered when conducting this research. One
of the primary limitations was the size of our sample, which limited power for further,
more granular analyses. This was especially true in our human subjects. Collecting CSF
and any other samples from humans is limited due to the nature of research on humans,
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but a longer-term study could accommodate for the needed increase in the study sample
size. Another limitation concerning our patient population is the absence of a control
population. A control population would be possible for our plasma samples in a longerterm study but would be more difficult to obtain for our CSF samples due to the more
invasive nature of its collection. With a larger scale study, we could possibly compare the
inflammatory environment from aSAH patients to populations of hydrocephalus patients,
TBI patients, or some alternative neurological group that also require spinal fluid
drainage on a serial basis.
Another limitation is the direct comparison of ICH and aSAH results for a
generalized conclusion of hemorrhagic stroke. While both conditions are a form of
hemorrhagic stroke, they occur in different areas of the brain; aSAH occurs from the
bursting of a blood vessel in the subarachnoid space, while ICH most commonly occurs
within the brain parenchyma. The differences in the location results in interactions of
different tissue types and anatomical structures with leukocytes, which may result in
unique inflammatory responses. Thus, with increased time and resources, it would be
valuable to run similar investigations in both types of stroke to obtain these comparisons.
Future Directions
There are countless scientifically exciting questions that rise from this work.
Perhaps the most obvious first direction is to investigate the possible relationship between
the cytokines IL-6 and IL-8 and the TXNIP-NLRP3 inflammasome. It is known that IL-6
may be tangentially related to the NLRP3 inflammasome. Indeed, IL-6 levels are
regularly increased in NLRP3 inflammasome-mediated conditions and are known to be a
downstream target of IL-1β. Thus, IL-1β-driven inflammation and NLRP3 activation was
shown to increase IL-6 (McGeough et al., 2012). This suggests that IL-6 does not have a
direct role in the inflammasome-mediated response but rather is a marker for the
response. It would be valuable to better investigate this relationship and how it may relate
to hemorrhagic stroke.
It would also be valuable to expand the use of verapamil treatment to a model of
aSAH. Running an experiment investigating the effect of verapamil in the aSAH model
will illuminate important similarities and differences between ICH and aSAH. The
mechanical differences between ICH and aSAH, such as site of action, are understood,
but the specific inflammatory cytokine response is not deeply understood. Investigating
the effect of verapamil on cytokine levels and the TXNIP-NLRP3 inflammasome will
highlight these differences. These experiments will allow us to understand if verapamil’s
success in improving outcomes following ICH is based more so on the anatomical nature
of ICH and the drug’s anti-hypertensive effects or if it is specifically due to gross
inflammasome interactions. This will also allow for the ability to understand the primary
mechanism by which verapamil acts to improve outcomes following hemorrhagic stroke
generally.
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Lastly and possibly also most importantly (for potential translational
implications), we should investigate the inflammatory response following aSAH and the
effect of drugs more commonly used in humans as adjunct therapies. For instance,
nimodipine is a calcium channel antagonist that increases cerebral blood flow through the
dilation of cerebral arterioles. Pharmacological studies in both animal models and
humans have shown improvements in mortality, rated alertness, and recovery (Langley &
Sorkin, 1989; Scriabine & Van den Kerckhoff, 1988; Wadworth & McTavish, 1992).
While this pharmacologic is widely used in practice, data are still needed on control and
dosing effects relative to the inflammatory effects of hemorrhagic stroke. Running similar
experiments to ours presented in Chapter 4, but instead utilizing this drug, will better
inform the mechanisms of action and better inform treatment timescale, dosage, and
administration for clinical practice in an accurate animal model of neuroinflammation.
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APPENDIX. PRO- AND ANTI-INFLAMMATORY CYTOKINE INVESTIGATIONS OUTLINED
Table A-1.

Summary of cytokines, tissue types, and species utilized in selected research papers.
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Al-Tamimi et al., 2019
Coulibaly et al., 2020
Moraes et al., 2020
Al-Tamimi et al., 2019
Chaudhry et al., 2017
Du et al., 2020
Wang et al., 2017
Guo et al., 2020
Al-Tamimi et al., 2019
Lv et al., 2018
Chaudhry et al., 2017
Huang et al., 2015
Gong et al., 2018
Wu et al., 2016
Xie et al., 2020
Xu et al., 2021
Zeng et al., 2020
Yagi et al., 2015
Lu et al., 2018
Tu et al., 2018
Mitsui et al., 2020
Wang et al., 2020
Li et al., 2020
Zhang et al., 2015
Chen et al., 2021
Zhao et al., 2016

Table A-1.

(Continued).

Cytokine of Interest

Brain

CSF

Tissue Type
Plasma
Serum

ISF

Human

Species
Mouse Rat

Rabbit

Tumor necrosis factor alpha (Continued)

X

X

X

88

Study
Wei et al., 2017
Wu et al., 2018
Wu et al., 2015
Zhang et al., 2015
Cai et al., 2017
Aydin et al., 2017
Fang et al., 2016
Xu et al., 2017
Hu et al., 2018
Luo et al., 2020
Hu et al., 2021
Wu et al., 2015
Liu et al., 2019
Liu et al., 2016
Fan et al., 2017
Xu et al., 2017
Li et al., 2016
Wang et al., 2019
Yin et al., 2018
Wang et al., 2017
Chen et al., 2016
Xia et al., 2017
Shi et al., 2015
Zhong et al., 2016
Li and Han, 2018
Xu et al., 2021
Zhang et al., 2016
Peng et al., 2018
Peng et al., 2018
Hao et al., 2016
Gu et al., 2017
Xu et al., 2021
Wang et al., 2021
Chen et al., 2019
Lu et al., 2018
Shi et al., 2015
Zhang et al., 2019
Shi et al., 2019

Table A-1.

(Continued).

Cytokine of Interest

Brai
n

Tissue Type
CSF

Plasma

Serum

ISF

Human

X

Tumor necrosis factor alpha
(Continued)

X
X

X
X

Transforming growth factor
beta 1

Species
Mous
Rat
e

X

X

X
X

X

Notes: CSF = Cerebrospinal fluid, ISF = Interstitial fluid
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Rabbit

Study(s)
Al-Tamimi et al., 2019
Zhou et al., 2015
Wu et al., 2016
Lv et al., 2018
Al-Tamimi et al., 2019
Wenneberg et al., 2021
Chen et al., 2017
Chen et al., 2020
Xu et al., 2021
Wang et al., 2020
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